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1CHAPTER I
INTRODUCTION
Antibiotics
The emergence of antibiotics as treatment for bacterial infections has been vital to
continued human health.  The term ‘antibiotic’ designates a chemical compound, either
natural or synthetic, that disrupts the structure or function of a bacterium without
simultaneously damaging its eukaryotic host (1).  Antibiotic use of sulfonamides and
penicillin began in the 1930’s, dramatically decreasing the number of deaths that resulted
from infectious diseases--previously the foremost cause of worldwide mortality and
morbidity.
To date, 17 different antibiotic classes have been identified, the majority of which
interfere with microbial biosynthesis of cell walls, proteins, DNA, or RNA.  The cell walls of
both Gram-positive and Gram-negative bacteria possess a peptidoglycan layer that
withstands the microbes’ strong intracellular pressure.  Several classes of antibiotics target
enzymes that form the peptidoglycan, rendering the bacterium vulnerable to osmolysis.
Other antibiotics perturb protein synthesis, a common target due to the dissimilarity of
ribosomal machinery between the bacterium and its multicellular host.  A third antibiotic
class interferes with DNA or RNA replication by targeting various proteins involved in
transcription or the unwinding of supercoiled DNA.  Still other antibiotics disrupt folic acid
metabolism or cell membrane integrity (Table 1) (1,2).
2Table 1.  Antibiotic classes and their mechanisms of action.  [Adapted from (2)].
Antibiotic Resistance
Unfortunately, despite the tremendous progress that has been made in the discovery
and administration of antibiotics, microbes have developed resistance toward every drug on
the market.  The rampant drug resistance problem significantly contributes to infectious
diseases being the second highest cause of death today (2).  A consequence of the
“survival of the fittest” rule of biology, microorganisms have acquired ways to adapt to drugs
that were once lethal to them.  Bacteria occasionally develop this resistance by spontaneous
gene mutation but more commonly by transmission of a resistance gene from another
bacterium.  Resistance genes are usually transmitted through mobile genetic elements
called transposons or more complex fragments called integrons, which contain multiple
resistance genes and can thereby confer resistance to several antibiotics at once (1).
Resistance can occur by three main mechanisms: A) development of a transport system that
shuttles the antibiotic outside the cell or reduces influx, B) modification of the bacterial target
so that the antibiotic can no longer bind to it, or C) evolution of enzymes that modify and
inactivate the antibiotic (Figure 1) (1,2).  This third mechanism is responsible for continued
resistance to the once potent antibiotic fosfomycin.
Mechanism of action Antibiotic families
Inhibition of cell Beta-lactams (penicillins, cephalosporins,
   wall synthesis carbapenems, monobactams); glycopeptides;
cyclic lipopeptides (daptomycin)
Inhibition of protein Tetracyclines; aminoglycosides;
  synthesis oxazolidonones (linezolid); streptogramins
(quinupristin-dalfopristin); ketolides;
macrolides; lincosamides
Inhibition of DNA Fluoroquinolones
  synthesis
Inhibition of RNA Rifampin
  synthesis
Competitive inhibition Sulfonamides; trimethoprim
  of folic acid synthesis
Membrane disorganizing Polymixins (Polymixin-B, Colistin)
  agents
Other mechanisms Metronidazole
3Figure 1.  Three main routes to antibiotic resistance.  A) increasing efflux or decreasing
efflux, B) modification of antibiotic target, C) chemical inactivation of antibiotic.  [Adapted
from (1)].
Fosfomycin
Fosfomycin, (1R-2S)-epoxypropylphosphonic acid, was first isolated from
Streptomyces cultures in 1969 as a broad-spectrum antibiotic against both Gram-positive
and Gram-negative bacteria (Figure 2) (3,4).  The compound was found to disrupt the first
step of cell wall biosynthesis by inhibiting the reaction between UDP-GlcNAc) and PEP,
which is catalyzed by the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase
(MurA).  In the uninhibited reaction, PEP attacks the 3’-OH of UDP-GlcNAc to form
enolpyruvyl UDP-GlcNAc and organic phosphate (Figure 3a).  Fosfomycin acts as a
substrate analog of PEP and forms a covalent thioether bond to MurA’s active site residue
Cys115, thereby inactivating the enzyme (Figure 3b).  Without proper functioning of MurA,
cell wall biosynthesis halts and the cell dies (5-7).  The exquisite specificity of fosfomycin for
its enzyme target can be attributed to the phosphonate’s position in MurA’s anionic binding
pocket, as well as the lack of fosfomycin homologues due to the unusual steric properties of
oxirane rings (7).
C
B
4Figure 2.  Structure of fosfomycin.
Figure 3. (a)  First step of cell wall biosynthesis, catalyzed by MurA.  (b)  MurA reaction is
inhibited by fosfomycin.
Fosfomycin is predominantly used to orally treat bacterial urinary tract infections in a
single dose and is a clinically desirable compound because of its low toxicity and few side
effects in humans.  The FDA has even designated fosfomycin a safe drug to use during
pregnancy (8, 9).  Fosfomycin has been proven effective against bacterial infections
resistant to other antibiotics as well; it has been used to combat vancomycin-resistant
enterococci (10) and quinolone-resistant E. coli (11).
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Figure 1.  (a) Reaction catalyzed by MurA.  (b) MurA inactivation by fosfomycin.
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5Fosfomycin Resistance and the Discovery of FosA
Soon after fosfomycin’s introduction to the clinic, however, resistance to the drug
was observed in several patients.  Although early instances of resistance were due to
chromosomal mutants that lost the ability to import fosfomycin (12, 13), eventually bacterial
plasmids were found to encode resistance elements of an enzymatic nature (14, 15).
Subsequent analysis of this first enzyme shown to inactivate fosfomycin revealed that the
resistance was caused by adduct formation between fosfomycin and the sulfhydryl of
glutathione, a reaction catalyzed by glutathione S-transferase (16, 17).  This reaction opens
the epoxide ring to render fosfomycin inactive against its target protein.  The 16 kDa enzyme
conferring resistance was named FosA and has since been designated a member of the
Vicinal Oxygen Chelate (VOC) superfamily.  Proteins in this group are characterized neither
by the types of reactions they catalyze nor by transition state structure, but by the common
presence of an electrophilic metal ion that participates in catalysis via two or more
accessible coordination sites (18).  Members of the VOC group are composed of paired
βαβββ motifs arranged in different orientations to form the metal ion binding site (Table 2)
(19).  In the case of dimeric FosA, the metal sites adopt a domain-swapped arrangement to
bind one metal ion per subunit (20).  FosA’s preferred metal is Mn2+, but it will use other
divalent metal cations with lower affinity (21).  In addition, K+ is required for maximal activity
of the enzyme and is presumed to aid in charge neutralization at the metal center to allow
approach of a glutathione anion to the binding site (Figure 4) (22).
Table 2.  Members of the VOC superfamily.
6Figure 4.  Crystal structure of Pseudomonas aeruginosa FosA with monomers depicted in
orange and blue.  Mn2+ and K+ ions are purple and green spheres, respectively.  [Adapted
from (49)].
Continued Emergence of Fosfomycin Resistance Proteins
Through sequence database searches, several FosA homologues have been
identified, and the mechanistic differences among them have led to their separation into
three distinct categories: FosA, FosB, and FosX.  Although each of the classes confers
resistance to fosfomycin, they do so with different substrates and metal ion dependencies
(Figure 5).  Unlike FosA, FosB enzymes use L-cysteine as the thiol donor rather than
glutathione and prefer Mg2+ to Mn2+.  Their activities are unaltered by monovalent cations.
The evolution of an enzyme using L-cysteine as an alternative thiol likely stems from the fact
that organisms encoding FosB do not make glutathione.  However, FosB shows only
modest catalytic activity and resistance capability compared to the robust FosA (23).
7Figure 5.  Reactions catalyzed by the three classes of fosfomycin resistance proteins.
The FosX enzymes differ from the previous two classes in that they act as epoxide
hydrolases, catalyzing the addition of water to fosfomycin to yield the diol product 1,2-
dihydroxypropylphosphonic acid. FosX structures have proven complementary to FosA in
several regions including the active site.  An overlay of the FosA and FosX active sites
reveals some similarities in metal binding and substrate recognition sites, but an important
difference is residue E44 in FosX (corresponding to G37 in FosA), which acts as a general
base for the conjugation of water to fosfomycin (Figure 6).  FosX activity does not require a
monovalent cation, and residues corresponding to the FosA K+ binding loop show
no electron density in FosX crystal structures (24).  While most FosX enzymes use Mn+2 as
their preferred metal, recent data reveals that some enzymes exhibit optimum catalytic
activity with Cu+2 instead (unpublished observations).  Kinetic and biological properties of
several characterized fosfomycin resistance proteins are displayed in Table 3.
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8Figure 6.  Overlay of FosA active site (green) and FosX active site (pink).  Residues are
numbered according to FosX sequence.  Equivalent positions in FosA, listed clockwise from
lower left, are G37 (green dot), T9, H64, H7, E110, and R118.  [Adapted from (24)].
Table 3.  Catalytic and resistance properties of several fosfomycin resistance proteins.
TN=transposon, PA=Pseudomonas aeruginosa, BS=Bacillus subtilis, SA=Staphylococcus
aureus, ML=Mesorhizobium loti, LM=Listeria monocytogenes.  [Adapted from (32)].
k cat k cat / K M
fos MIC
Protein (s
-1) (M-1 s-1) mg/mL MW
FosATN 660 ± 10 (1.4 ± 0.1) x 107 >20 15889
FosAPA 175 ± 6 (9.0 ± 1.4) x 105 >20 15114
FosBBS 4.8 ± 0.3 (4.0 ± 0.5) x 103 0.1 17173
FosBSA 0.99 ± 0.02 (9.2 ± 0.1) x 103 0.4 16637
FosXML 0.15 ± 0.02 (5.0 ± 0.6) x 102 0.025 16181
FosXLM 34 ± 2 (9 ± 2) x 104 >20 15655
None <0.025
9The data presented herein concern the FosX enzymes encoded in two microorganisms,
Listeria monocytogenes and Pseudomonas putida.  A brief discussion of these species is
necessary to understand the relevance of this project.
Listeria monocytogenes
Listeria monocytogenes is a Gram-positive, food-borne pathogen that can grow at
temperatures as low as 3°C, which allows it to survive in refrigerated foods and makes it
virtually undetectable.  It is normally soil-dwelling but has also been isolated from wild and
domesticated animals, insects, soil, water, and vegetation.  As is the case for many bacterial
species, people at highest risk for acquiring a Listeria infection are immunocompromised
patients and pregnant women, for whom the fetal mortality rate is 80%.  Following
gastrointestinal symptoms, more serious disorders including meningitis and encephalitis
often develop.  However, since early symptoms resemble the flu, they are frequently ignored
until the bacteria have multiplied and spread throughout the nervous system to cause
irrevocable damage.  Listeria infection is quite dangerous; in the year 2000, 95% of people
infected with the bacteria required hospitalization (Figure 7), and over 20% of cases resulted
in death (Figure 8).  These numbers are in stark contrast to more commonly mentioned
food-borne pathogens such as E. coli and Salmonella (25).
Figure 7.  Percentage of hospitalizations from food-borne infections in 2000.  [Adapted from
(25)].
10
Figure 8.  Percentage of fatalities from food-borne infections in 2000.  [Adapted from (25)].
Pseudomonas putida
Pseudomonas putida is a saprophytic Gram-negative microorganism that has
typically been considered non-pathogenic.  It is soil-dwelling and has rarely been isolated
from clinical specimens, so little is known about its capacity to cause human infection.
Resistance to P. putida is poorly understood, since it is usually susceptible to standard
antimicrobial agents.  However, many experts believe that it has the capacity to become as
resistant as its dangerous relative Pseudomonas aeruginosa, with which it shares 85% of its
gene coding regions.  P. putida shows a remarkable ability to decompose many carbon
sources that other organisms cannot; therefore, it is not surprising that the bacterium could
develop resistance to the fosfomycin molecule.  The putative resistance protein studied in
this work is located on an integron, making it even more dangerous because the genetic
element also contains resistance enzymes β-lactamase and aminoglycoside
acetyltransferase (Figure 9).  The Pseudomonas putida FosX on this integron shares over
50% identity to established FosX enzymes  (Figure 10) (26-28).
Figure 9.  Structure of antibiotic resistance integron isolated from Pseudomonas putida.
Modeled after GenBank accession number AY065966.
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Figure 10.  Sequence homology of Pseudomonas putida FosX (“Query”) and Listeria
monocytogenes FosX (“Sbjct”).  Residues in red are metal-binders, green are catalytic
bases, and blue are fosfomycin recognition sites.
>gi|46395924|sp|Q8Y6I2|FOSX_LISMO  Fosfomycin resistance protein fosX
          Length=133
 Score =  162 bits (411),  Expect = 2e-40
 Identities = 74/130 (56%), Positives = 97/130 (74%), Gaps = 0/130 (0%)
Query  10   MEGISHITLIVRDLSRMTTFLCDGLGAREVYDSAGHNYSLSREKFFVLGGVWLAAMEGVP  69
            + G+SHITLIV+DL++ TTFL +   A E+Y S    +SLS+EKFF++ G+W+  MEG
Sbjct  2    ISGLSHITLIVKDLNKTTTFLREIFNAEEIYSSGDQTFSLSKEKFFLIAGLWICIMEGDS  61
Query  70   PSERSYQHVAFRVSESDLAVYQARLGSLGVEIRPPRPRVNGEGLSLYFYDFDNHLFELHT  129
              E++Y H+AFR+   ++  Y  R+ SLGVEI+P RPRV GEG S+YFYDFDNHLFELH
Sbjct  62   LQEQTYNHIAFRIQSEEVDEYIERIKSLGVEIKPERPRVEGEGRSIYFYDFDNHLFELHA  121
Query  130  GTLEQRLARY  139
            GTLE+RL RY
Sbjct  122  GTLEERLKRY  131
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Purpose
Antibiotic resistance is a dangerous consequence of a bacterium’s ability to adapt to
harmful environments.  Drugs that once easily eradicated common illnesses have in many
cases been rendered useless by the mounting resistance problem.  To resolve this global
healthcare issue, we must strive to learn all we can about the molecular bases of drug
resistance so that we may devise new treatments for infectious diseases.  This work
discusses the FosX fosfomycin resistance proteins found in Listeria monocytogenes and
Pseudomonas putida, as a thorough understanding of the chemical and biological properties
of these enzymes is essential to restoring the power of fosfomycin as a robust antimicrobial
agent.  Knowledge of these proteins may one day lead to development of small molecule
inhibitors that will lessen or eliminate bacterial resistance to this antibiotic.
13
CHAPTER II
HYDROGEN/DEUTERIUM EXCHANGE MASS SPECTROMETRY CONCEPTS AND
ANALYSIS
Theory
Hydrogen/deuterium exchange mass spectrometry (HXMS) is a powerful technique
that uses solvent accessibility of amide hydrogen atoms along a protein backbone to predict
the solution structure of the protein.  Linderstrøm-Lang first conceptualized the idea that the
rate of amide hydrogen exchange with solvent molecules is a reflection of the protein’s
rigidity.  Hydrogen atoms on a polypeptide such as the one shown in Figure 11 will
exchange with solvent hydrogen (or deuterium) at different rates.  The hydrogens colored
green in the figure are covalently bonded to carbon atoms and hence do not undergo
exchange.  The blue ones, making up the side chains, exchange at rates too rapid to be
detected by conventional methods.  Finally, the red hydrogens, which compose the
backbone amides of all amino acids except proline, exchange at measurable rates
depending on such factors as protein structure and solution pH (29).
Figure 11.  Three types of hydrogen atoms within a protein.  [Adapted from (29)].
At neutral pH and with D2O as solvent, OD
- will abstract these protons in a base-
catalyzed reaction.  The speed and efficiency of base catalysis is a function of each amide
hydrogen’s placement in the folded protein and can be described as lying on a continuum
between immediate exchange and exchange that occurs only after complete unfolding of the
protein.  The fastest exchange is called “EX2” and results when refolding of the protein
happens more quickly than the intrinsic rate of hydrogen exchange for deuterium.  The rate
expression for this process shows that the observed rate depends on the equilibrium
constant between folded and unfolded protein states.  On the other end of the continuum is
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the “EX1” regime, whereby exchange occurs more quickly than opening of the protein and
exposure of the amide hydrogen to solvent.  Thus the observed rate for EX1 is defined as
the rate of protein unfolding (Figure 12).  In short, if the proton is engaged in hydrogen
bonding or is part of tight secondary structure, the dynamic fluctuations that must occur for
the proton to become solvent accessible will result in slower exchange rates.  If the proton is
in a more accessible region, then OD- can approach more easily and faster exchange will
occur.  These rates can be monitored using mass spectrometry and reflect conformational
changes that accompany ligand binding and enzyme catalysis (30, 31).
Figure 12.  Schematic of hydrogen/deuterium exchange in a folded protein with
representative rate expressions.  [Adapted from (31)].
Experimentation
To determine the proton-deuterium exchange rates for the backbone protons, the
protein must be proteolytically cleaved at as many residues as possible to attain the greatest
spatial resolution.  The ideal situation would be to cleave enough overlapping peptides to
enable calculation of every amide hydrogen exchange rate.  While this has not yet been
ki ko
kc
kc
kc
ko
kex=ko/ki (ko + kc + ki)
EX2: kc>>ki; kex = (ko/kc)/ki
EX1: ki>>kc; kex = ko
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accomplished, the resolution can be significantly improved by using multiple proteases.
This creates what is called a peptide map and is generated by incubating the protein with
each acid protease that will be used in the HXMS experiments and sequencing the
fragments using tandem MS/MS.  The fragments are then used as reference points from
which to calculate the mass increase upon hydrogen exchange with solvent deuterium.
Amide hydrogen exchange is temperature- and pH-dependent, as shown in Figure
13.  To take advantage of this property, the protein is initially incubated with solvent D2O for
a range of time points at room temperature and neutral pH, where exchange occurs rapidly.
Then to effectively “trap” deuterium onto the protein to prevent back-exchange to hydrogen,
chilled acidic quench solution is added followed by an acid protease that cleaves along the
backbone.  The entire sample is then placed on ice for several minutes to further prevent
back-exchange.  At this point, protein cleavage is complete, and the solution is injected onto
a reverse-phase HPLC column, and peptides are separated with a mobile phase gradient.
Because electrospray ionization is used, the output of the HPLC becomes the input of the
MS as fine droplets of the sample are sent to the mass analyzer (Figure 14) (30, 31).
Figure 13.  pH dependence of hydrogen exchange rates.
Pulse
D2O
Quench
D2O
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Figure 14.  Schematic of HXMS experiment.  [Adapted from (31)].
Analysis
To analyze deuterium incorporation into the protein, each of the peptides detected
from the map is again detected in the deuterated spectra, but the masses will be shifted to a
value dependent upon the extent of exchange for deuterium, a heavier isotope.  The
masses will appear as roughly symmetrical peaks separated by one mass unit for each
deuterium that has been added.  These values must be corrected for the amount of
exchange occurring during the digest itself, which is called the 0% control for the reaction.
All values are also placed in the context of the maximum possible exchange, the 100%
control, which is determined by incubating the protein for a longer time (ideal time is
determined experimentally) and at a high temperature to facilitate unfolding.  Masses at
each time point must be averaged using the same size mass envelope to ensure that values
are normalized (30, 31).  Further details of the analysis are included in the Methods section
of this work.
15 sec-6 hr
25°C, pH 7.5
Quench
0°C, pH
2.4
Pepsin
0°C, pH
2.4
Reverse-phase
HPLC
ESI-MS
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CHAPTER III
MATERIALS AND METHODS
Materials
E. coli Rosetta (DE3) cells and XL1-Blue cells were from Novagen (San Diego, CA).
BL-21 (DE3) cells were from Stratagene (La Jolla, CA).  LB media, ampicillin, MOPS, IPTG,
MES, and DTT were from RPI (Mt. Prospects, IL).  Chloramphenicol, kanamycin, lactose,
pepsin, Aspergillus saitoi protease XIII, Rhizopus protease XVIII, potassium phosphate,
formic acid, HEPES, agarose, TRIS, EDTA, lysozyme, P2714 protease inhibitor,
streptomycin sulfate, CHES, glutathione, and L-cysteine were from Sigma (St. Louis, MO).
Acetonitrile, NaCl, and KCl were from Fisher (Hampton, NH).  All metals (puratronic grade)
in their chloride salt form were from Alfa Aesar (Ward Hill, MA).  D2O and TMA were from
Acros (Geel, Belgium).  Wizard DNA Purification System was from Promega (Madison, WI).
Restriction enzymes NdeI and XhoI and ligation kit were from New England Biolabs
(Ipswich, MA).  Chelex 100 resin was from Bio-Rad (Hercules, CA).  Fosfomycin was from
Fluka (Ronkonkoma, NY).  SP Sepharose Fast Flow resin was from Amersham Biosciences
(Uppsala, Sweden).
Methods
Expression of Listeria monocytogenes FosX
The expression plasmid for gene lmo1702 was constructed and transformed into E.
coli Rosetta (DE3) cells as previously described (32).  Two 1.3 L cultures were inoculated
with bacteria from an overnight starter culture (incubated approx. 13 hrs at 28.5°C and
shaken at 160 RPM) to reach a starting OD600 of 0.025.  Starter and inoculated cultures
contained LB media, 80 µg/mL ampicillin, and 18 µg/mL chloramphenicol.  Inoculated
cultures were incubated at 30°C and shaken at 225 RPM until reaching an OD600 of 0.6.
Protein overexpression was induced with 1 mg/mL lactose for 5-6 hrs.  Cells were harvested
by centrifugation and stored at -80°C.
Purification of L. monocytogenes FosX
Purification was carried out as previously described (32).
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Identification of L. monocytogenes FosX Peptic Fragments
Pepsin digests using a 1:1.5 FosX:pepsin w/w ratio were performed under the
quenching conditions of the HXMS experiment.  71 µg of FosX (5 µL) in 20-25 µL quench
buffer (0.1 M potassium phosphate, pH 2.4) was digested by adding 106.5 µg of pepsin (3.6
µL of 30 mg/mL solution in H2O) for 5 mins on ice (0°C).  The pepsin-digested peptides were
separated by reverse-phase HPLC using a ThermoFinnigan Surveyor HPLC (San Jose, CA)
and identified by tandem ESI-MS/MS sequencing as peptides are eluted.  Peptides were
first separated on a Jupiter 50 x 1.00 mm C18 column (Phenomenex, Torrance, CA) using a
mobile phase gradient of buffer A (98% H2O, 2% acetonitrile, 0.4% formic acid) and buffer B
(98% acetonitrile, 2% H2O, 0.4% formic acid) over 25 mins (0.1 mL/min). A six-port divert
valve was used to send early-eluting contaminant species to waste.  Peptides were
sequenced using a ThermoFinnigan TSQ triple quadrupole mass spectrometer (San Jose,
CA) in positive-ion mode by data-dependent tandem MS/MS collision-induced dissociation
(33, 34).  Capillary temperature=190°C, scan time=4 s, peak width=0.2, collision energy=25
and 40, scanned 300-1500 m/z.  Data processing was performed using Finnigan Xcalibur
software (version 1.3).  The identities of the peptides were determined using ExPASy-
PeptideMass software (35) and were confirmed by analysis of the MS/MS sequencing of
individual peptides by comparison to theoretical fragmentation patterns generated by the
ProteinProspector program MS-Product (36).
Digests using Aspergillus saitoi protease XIII were performed using a 10:1 FosX:
protease XIII w/w ratio.  Digests using Rhizopus protease XVIII were performed using a 16:1
FosX: protease XVIII w/w ratio (37).  Both cleavages were done under the same quench and
digestion conditions, solvents, and instruments as described for pepsin above.  As these are
rare proteases whose cleavage patterns are unknown, the alternate Macintosh-based
program Sherpa version 3.3.1 (Alex Taylor, University of Washington), which calculates all
possible cleavage species, was used to analyze MS/MS sequencing of individual peptides
generated by these enzymes.  FosX maps obtained from each protease are shown in
Appendix A.
HXMS Protocol
FosX protein used in HXMS was dissolved in 20 mM MOPS buffer, pH 7.5.  For
apoprotein or protein bound to Mn2+, Co2+, or Zn2+, deuterium exchange was initiated by
adding 45 D2O to 5 µL of 400 µM protein solution.  Metal stocks were prepared at approx.
10 mM in degassed H2O at pH 7.0, and 1:1 eq. metal:FosX was incubated for at least 10
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minutes preceding the addition of D2O to ensure binding saturation.  The protein/D2O
solution was incubated at 25°C for various times between 15 s and 6 hrs.  At each time
point, the reaction was quenched by placing the tube on ice and adding 50 µL of quench
buffer listed above.  After 30 s, 1.5 eq. pepsin:FosX w/w (30 mg/mL in H2O) was added to
the quenched sample and incubated on ice for 5 min.  All of the samples for each day of
HXMS were prepared and run individually (33, 34).
0% and 100% Control Experiments
To determine the amount of deuterium incorporated during the digest step so that it
can later be subtracted from the exchange at each time point (m0%), 50 µL quench buffer
was added to 5 µL of 400 µM protein solution, immediately followed by 45 µL D2O.  After 30
s incubation, 1.5 eq. pepsin:FosX was added and the sample digested on ice for 5 mins.
The fully deuterated sample is also used a control in the mathematical analysis of
partial deuteration.  This sample (m100%) is obtained by incubating FosX and D2O for an
extended period of time (8 hrs here) at a high temperature (50°C here) to allow the protein
to unfold.  Acidic quench buffer and pepsin are then added as for the partially deuterated
samples (33, 34).
HPLC/ESI-MS
The HPLC injection loop and gradient solvents were kept submerged in ice (0° C) for
the entirety of the experiment to minimize deuterium-hydrogen back-exchange.  The
peptides were separated over 12 mins with a 2-60% gradient of buffers A and B.  Peptides
were separated and mass-analyzed as described above.  The mass spectrometer was
operated in full scan mode using Quad 1.  Capillary temperature=190°C, scan time=1 s,
peak width=0.7, collision energy=15, scanned 300-1500 m/z.  MagTran 1.0 beta 9 software
was used to determine the centroid of the mass envelope (38).
Kinetic Analysis
The amount of deuterium incorporated into each peptide as a function of time is
adjusted for the gain (m0%) and loss (m100%) of deuterium during analysis.  The corrected
deuteration is defined by the following expression:
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where m0% represents the nondeuterated average mass of a peptide, mt is the partially
deuterated average mass at time t, and m100% is the fully deuterated average mass.  N is the
total number of exchangeable amide protons minus one for each N-terminal residue and any
prolines contained on the peptide.  Native protein results were the average of three data
sets, Mn2+-bound protein the average of five, and Co2+- and Zn2+-bound protein the average
of two each.  Deuterium incorporation was plotted versus time according to the following
equation using the program Prism version 4.0a (Graphpad Software), where D is the
number of incorporated deuterons, N is the total number of exchangeable amide protons, An
is the number of deuterons incorporated for the rate constant described by knt, and t is the
incubation time.  For FosX, all traces were fit to either single- or double-exponential
equations (33, 34).
Absorbance Spectroscopy
To probe binding properties of FosX for divalent metal ion cofactors, proteins are
titrated with increasing amounts of metal in order to observe changes in intrinsic protein
absorbance.  Binding experiments using 100-200 µM protein were carried out in 20 mM
TMA-MOPS, pH 7.5, 25°C.   Optical spectra of native protein and protein plus each aliquot
of metal titrant (5 µL increments) were collected on a Perkin-Elmer lambda 45 double-beam
spectrophotometer (Wellesley, MA) with 2 min protein-metal equilibrations prior to the
absorbance scan of 240-700 nm.  Precise concentration of protein in the cuvette was
determined from ε280 = 1.34 x 10
4 M-1 cm-1.  Spectra were corrected for background by
establishing baseline at A650, subtracting starting apoprotein spectrum, and correcting for
dilution.  Binding saturation was monitored by calculating the absorbance difference
between 470 nm and 424 nm.  Corrected absorbance was plotted against concentration to
determine the number of equivalents needed to saturate FosX binding sites (39, 40).  Plots
were generated with Microsoft Excel X.
Fluorescence Spectroscopy
In a preliminary experiment, optimal excitation wavelength was determined to be 290
nm, and peak emission wavelength was determined to be 340 nm.  Fluorescence
experiments using 5 µM protein were carried out in 25 mM TMA-HEPES, 150 mM NaCl, pH
7.5 passed through a 0.2 µm syringe filter.  Two-mL cuvettes that had been soaked in 10%
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HNO3 for >24 hours to eliminate contaminating metal species were thoroughly rinsed before
beginning the titrations.  Spectra of native protein and protein plus each aliquot of metal
titrant (8 µL increments) were collected on a Horiba Fluorolog, allowing 10 min protein-metal
equilibrations prior to each fluorescence scan.  Precise protein concentration at the onset of
the experiment was determined from  ε280 = 1.34 x 10
4 M-1 cm-1 on a Perkin-Elmer lambda 45
double-beam spectrophotometer.  Spectra were corrected for background and intrinsic
protein fluorescence, and corrected fluorescence was plotted against concentration to
determine the number of equivalents needed to saturate FosX binding sites.   Plots were
generated with Microsoft Excel X.
Cloning of Pseudomonas putida FosX
The gene containing the putative FosX enzyme from Pseudomonas putida with
codon optimization for expression in E. coli was ordered from the company DNA 2.0 (Menlo
Park, CA).  It was received in two forms: encoded in lyophilized plasmid pJ5:G02754
(trademarked by DNA 2.0 and containing kanamycin resistance cassette and desired
restriction sites for insertion into plasmid of choice), and transformed into an E. coli stab
culture for culture growth and DNA harvesting.  E. coli stab culture was streaked and plated
onto LB plates containing 30 µg/mL kanamycin.  After overnight growth at 37°C, an
individual colony was selected for small culture growth at 37°C and 225 RPM.  Plasmid DNA
was then extracted using Promega Wizard Miniprep kit.  The pJ5 plasmid and pET20b(+)
plasmid were digested simultaneously with 5’ restriction enzyme NdeI and 3’ restriction
enzyme xhoI, and incubated for 4 hrs at 37°C.  Digestion products were run on an agarose
gel and the proper molecular weight bands were excised and purified using Amicon
Ultrafree-DA spin columns.  FosX gene insert and linear pET20b(+) plasmid were ligated
using New England Biolabs ligation kit and transformed into XL-1 Blue cells.  Transformed
cells were plated onto LB plates containing 100 µg/mL ampicillin and placed in an incubator
at 37°C overnight.  DNA was harvested using Wizard kit.  Presence of FosX gene insert was
verified using PCR, and sequence was confirmed by submission to Vanderbilt Sequencing
Core.
Expression of P. putida FosX
pET20b(+) expression vector containing FosX gene was transformed into E. coli BL-
21 (DE3) cells for optimum protein expression.  One 1 L culture was inoculated with bacteria
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from an overnight starter culture (incubated approx. 14 hrs at 28.5°C and shaken at 165
RPM) to reach a starting OD600 of 0.025.  Starter and inoculated cultures contained LB
media and 100 µg/mL ampicillin.  Inoculated cultures were incubated at 30°C and shaken at
180 RPM until reaching an OD600 of 0.6.  Protein overexpression was induced with 0.4 mM
IPTG for 5 hrs.  Cells were harvested by centrifugation and stored at -80°C.
Purification of P. putida FosX
Cell pellets were thawed on ice and resuspended in 10-15 mL 25 mM TRIS buffer,
75 mM NaCl, 0.5 mM EDTA, pH 7.5 (buffer C).  To aid cell lysis, ~2 mg lysozyme was
added and cells incubated at 25°C for 1 hr with gentle rocking, and then incubated on ice
(0°C) for an additional hr.  Another 21 mL lysis buffer was added to cell suspension and
mixture was further lysed using a Bronson sonicator (70% duty cycle, 6-7 output control) in 4
x 3 min cycles with a 3 min pause between each.  Sigma P2714 protease inhibitor was
added after first cycle.  Cell debris was removed by centrifugation at 35,000 x g for 25 mins.
The supernatant was treated with 500 mg streptomycin sulfate dissolved in 1 mL H2O and
stirred for 1.5 hrs at 4°C to remove nucleic acids.  Centrifugation was repeated, and crude
lysate was dialyzed (all dialysis performed overnight in 4°C unless otherwise noted) in 2 L
25 mM MES buffer, 150 mM NaCl, 0.5 mM EDTA, pH 6.0 (buffer D).  In the morning,
centrifugation was again repeated to ensure removal of all nucleic acids and precipitated
proteins.  Lysate was passed through an SP Sepharose Fast Flow column equilibrated with
buffer D.  Column was washed with buffer D and protein was eluted using a linear NaCl
gradient (150-500 mM).  Fractions containing putative FosX were identified by absorbance
at 280 nm (ε280 = 1.465 x 10
4 M-1 cm-1) and SDS-PAGE analysis.  Fractions containing the
protein were pooled and dialyzed against 2 L demetalation buffer E (20 mM MOPS, 10 mM
NaCl, 5 mM EDTA, 0.5 mM DTT, 3 g Chelex resin, pH 7.5) for 2 days.  Protein was then
dialyzed in 2 L second dematalation buffer F (20 mM TMA-MOPS, 0.5 mM DTT, 2 g Chelex,
pH 7.5), followed by another dialysis into 2 L more of buffer F.  Protein was concentrated in
a nitrogen pressure cell using a 5K molecular weight cutoff membrane and stored at -80°C.
Identity was confirmed through MALDI mass spectrometry on an Applied Biosystems
Voyager instrument (Foster City, CA).  Final yield was 25 mg per L of culture.
Determination of Minimum Inhibitory Concentration of Fosfomycin
In agar.  Growth of E. coli BL21 (DE3) cells containing the Pseudomonas putida FosX
expression plasmid was compared to growth of cells containing Listeria monocytogenes
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FosX expression  plasmid, whose fosfomycin MIC value has been established, and empty
vector control.  Bacteria that had reached OD600 = 0.015 were streaked onto LB plates
containing 100 µg/mL ampicillin, 40 µM glucose-6-phosphate, and various concentrations of
fosfomycin (0-25 mg/mL, dissolved in H2O).  Plates were incubated at 37°C overnight and
subsequent growth was noted and photographed.
In liquid cultures.  Bacteria were added to 3 mL LB media containing 100 µg/mL ampicillin,
40 µM glucose-6-phosphate, and various concentrations of fosfomycin (0-20 mg/mL,
dissolved in H2O) to reach a final OD600 of 0.05.  To assess the effect of FosA growth
inhibitors Phosphonoformate (PF) and acetylphosphonate (AcP), 10-100 µM of either
compound were added to cultures containing 20 mg/mL fosfomycin.  All cultures were
incubated at 37°C and shaken at 225 RPM, and growth was recorded.
Determination of P. putida FosX Metal Preferences Using 31P-NMR Spectroscopy
A typical reaction involved 2.3 µM FosX preincubated for 10 mins with 100 µM Mn2+,
Fe2+, Ni2+, Co2+, Cu2+, or Ca2+, or with 1 mM Mg2+ or Zn2+, in 25 mM HEPES, pH 7.5.
Reaction was initiated by the addition of 25 mM fosfomycin (pH 7.5 in H2O) and allowed to
proceed for several hours as needed to observe 10-15% product turnover.  Reactions were
quenched with 100 µL CHCl3 and vigorous vortexing, followed by flash-freezing on dry ice.
After ≥30 mins, reactions were thawed, centrifuged to separate precipitated protein, and the
aqueous layer was gently rocked with Chelex resin for 1.5 hrs.  Chelex was pelleted and
removed, and the aqueous layer was used for NMR analysis after addition of solvent D2O.
Proton-decoupled spectra were collected at 121 MHz, with 31P chemical shifts of 16.9 ppm
for diol product and 11.1 ppm for fosfomycin.
Estimation of P. putida Turnover Number (kcat) Using 
31P-NMR Spectroscopy
Reactions were carried out exactly the same way as for determination of metal
preferences above.  Turnover numbers were estimated by calculating the ratio of substrate
and product peak heights and comparing to the amount of substrate used in the reaction,
which yields the extent of product turnover.
Determination of P. putida FosX Optimal pH Using 31P-NMR Spectroscopy
Reactions were carried out exactly the same way as for determination of metal
preferences above, but with different buffers in desired pH range.  The selected buffers
tested the reaction efficiency at pH 5.5 (25 mM MES), pH 6.5 (25 mM MES), pH 7.5 (25 mM
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HEPES), pH 8.5 (25 mM CHES), and pH 9.5 (25 mM CHES).
Determination of P. putida FosX Promiscuous Catalytic Activity Using 31P-NMR
Spectroscopy
Reactions were carried out exactly the same way as for determination of metal
preferences above, but with minor modifications.  To test ability of the enzyme to perform
the FosA reaction, enzyme was preincubated with 100 µM Mn2+ and initiated with 25-200
mM GSH (dissolved in H2O, pH 7.5).  Reaction buffer 25 mM HEPES pH 7.5 was prepared
with or without 100 mM KCl to test K+ activation of FosA reaction.  To test ability of the
enzyme to perform the FosB reaction, enzyme was preincubated with 100 µM Mg+2 and
initiated with 25-200 mM L-cys (dissolved in H2O, pH 7.5).  Reactions were quenched as
above.
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CHAPTER IV
LISTERIA MONOCYTOGENES FOSX DYNAMICS VARY BASED ON CATALYTIC METAL
AS DETERMINED BY HYDROGEN-DEUTERIUM EXCHANGE
MASS SPECTROMETRY
Many examples of decreased structural perturbations and protein dynamics upon
ligand binding to protein exist in the literature.  This work, however, includes the observation
of a rare phenomenon; increased solvent accessibility and global conformational changes
occur when divalent metal ion cofactors bind to Listeria monocytogenes FosX, the extent of
which is directly proportional to the metal’s ability to catalyze hydrolysis of FosX substrate
fosfomycin.  Previous work has shown that metal preference is as follows: Mn2+>Co2+>>Zn2+
(24).  (Note: Due to a flaw in the graphing program that was used to generate the plots
below, displaying more than one trace on the same plot causes the best-fit curves to appear
skewed as compared to plotting one trace alone.  However, the program generated identical
amplitude and rate constants regardless of how the traces were displayed.  To view the
curves separately and verify that the lines fit the data better than the plots in this section
seem to indicate, please see Appendix B.)
Results
Identification of Peptic Fragments
Three independently generated peptic maps with pepsin, Aspergillus protease XIII,
and Rhizopus protease XVIII yielded 98% overall protein coverage.  The pepsin map covers
85% of the protein, Aspergillus protease XIII covers 78%, and Rhizopus protease XVIII
covers 69%.  These contain several areas of heavy overlap permitting enhanced spatial
resolution.  Peptide maps showing all sequenced and identified peptides are in Appendix A.
FosX Dynamics at Metal Binding Residues
Crystal structures of this protein reveal three residues that coordinate a divalent
metal ion to the FosX dimer: H7, H69, and E118, and one additional questionable residue,
E126, that has not been shown to coordinate metal to the protein in any other organism
(Figure 15).  Intuitively, one would expect the structure of a protein to become more rigid
upon binding ligand, because the act of binding translates to increased structure and
therefore less solvent accessibility.  However, upon observation of FosX dynamics in the
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presence of three metal ion cofactors Mn2+, Co2+, and Zn2+, we learn that this assumption is
incorrect.
Figure 15.  Mn2+-bound FosX showing metal coordination residues and distances from Mn2+
center.
Metal binding residue H7.  The peptides 1-5 and 1-10 can be used to assess how metal
binding to FosX impacts residue H7.  Figure 16 and Table 4 show that while the exchange
behaviors of native enzyme and enzyme bound to Co2+ or Zn2+ are virtually identical,
exchange with bound Mn2+ is about 30% faster.  Comparing these rates with those of
peptide 1-5, showing very fast exchange that differs among the four species by 5% at most,
we deduce that the C-terminal half of peptide 1-10 is responsible for the differences in
exchange.  Peptide 6-10 was not found in enough HXMS trials to allow statistically
significant analysis, so the subtraction method must suffice here.  Therefore, increased
exchange in the area of residues 6-10, which includes binding residue H7, is Mn2+-
dependent, with HXMS profiles of Co2+- and Zn2+-bound protein nearly identical to native
enzyme.  Segment 6-10 is a β-strand on the crystal structure, while 1-5 is an unstructured
loop.
Mn
E118
H69
E126
H7
2.28
2.07
2.16
2.17
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Peptide 1-10 (9)
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Figure 16.  HXMS backbone amide kinetic profile for peptide 1-10.
Table 4.  Rate constants and amplitudes for peptides 1-5 and 1-10.
Metal binding residue E118.  Peptide 117-124 contains metal coordination residue E118.
FosX bound to Mn2+ exhibits an 87% fast exchange rate, followed by 73% for Co2+, followed
by Zn2+ and native protein which are roughly equal at 66% and 64%, respectively.  Although
this region of the protein exchanges quickly in all four species, the statistically significant
results are consistent with the fastest exchange occurring with the preferred divalent metal
Mn2+.  As the metal preference decreases to Co2+ and then Zn2+, so does the speed of
amide hydrogen exchange.  Plots and rate data are exhibited in Figure 17 and Table 5
below, with similar amplitudes and rates displayed for peptide 117-125 to show the
reproducibility of results gleaned from this technique.
sample peptide A1 (D) k 1  (min-1) A2 (D) k 2  (min-1)
Native 1-5 0.62 ± 0.04 0.04 ± 0.01
Mn2+ 0.46 ± 0.06 0.11 ± 0.05
Co2+ 0.57 ± 0.06 0.05 ± 0.02
Zn2+ 0.50 ± 0.09 0.06 ± 0.04
Native 1-10 4.0 ± 0.3 0.10 ± 0.02 2.6± 0.3 (1.7 ± 0.7) x 10
-3
Mn2+ 2.3 ± 0.7 1.4 ± 0.7 1.2 ± 0.3 0.016 ± 0.009
Co2+ 3.2 ± 0.1 0.16 ± 0.03 2.6 ± 0.1 (1.6 ± 0.3) x 10-3
Zn2+ 4.3 ± 0.2 0.3 ± 0.1 2.1 ± 0.3 (1.3 ± 0.3) x 10
-3
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Figure 17.  HXMS backbone amide kinetic profile for peptide 117-124.
Table 5.  Rate constants and amplitudes for peptides 117-124 and 117-125.
Peptide 110-116 comprising a turn between two β-strands shows an exchange
pattern that echoes the fast exchange trend of peptide 117-124 above.  This not only
provides verification that the results we see are likely correct, but also supports the notion
that the entire protein must orient itself in such a way as to facilitate metal binding.  It makes
sense that this peptide near a metal binding residue would experience a structural
perturbation to accommodate approach of the metal cation to the active site.  This peptide,
similar to 117-124, displays different kinetics for each of the four species in fast,
intermediate, and slow exchange regimes, suggesting both an increase in solvent dynamics
and a decrease in overall structure as the protein binds a more catalytically relevant metal
(Figure 18, Table 6).
Peptide 117-124 (7)
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sample peptide A1 (D) k 1  (min-1) A2 (D) k 2  (min-1)
Native 117-124 2.55 ± 0.09 (2.8 ± 0.6) x 10-3
Mn2+ 0.9 ± 0.1 0.21 ± 0.09
Co2+ 1.9 ± 0.1 (3.2 ± 0.9) x 10-3
Zn2+ 2.2 ± 0.1 (3.3 ± 0.8) x 10-3
Native 117-125 1.6 ± 0.3 1.1 ± 0.4 2.3 ± 0.1 (2.1 ± 0.4) x 10-3
Mn2+ 1.10 ± 0.08 0.10 ± 0.03
Co2+ 1.9 ± 0.1 0.020 ± 0.005
Zn2+ 2.2 ± 0.2 0.010 ± 0.004
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Peptide 110-116 (6)
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Figure 18.  HXMS backbone amide kinetic profile for peptide 110-116.
Table 6.  Rate constants and amplitudes for peptides 110-116.
Putative metal binding residue E126.  One crystal structure of Listeria monocytogenes FosX
shows that residue E126 is within coordination distance of the divalent Mn2+ cation.
Although several short peptides spanning the C-terminal tail region were pinpointed in
mapping experiments, the only one for which a consistent signal was observed during
HXMS experiments was the long peptide 125-133, an α-helix in the structure.  Since HXMS
amplitudes and rate constants are averages of every amide hydrogen exchange along a
peptide, it is impossible to deduce the dynamic properties at the precise residue E126.
From Figure 19 and Table 7, however, we can equivocally state that exchange is very fast in
the region around E126--about 80-85% for Co2+ and Zn2+, 100% for Mn2+ (program could not
fit data because exchange was complete by 15s), and 50% for apoenzyme (Although the
best-fit lines look quite similar for the four species, the few low points at the beginning of the
time course for native enzyme have been quite reproducible and should not be considered
outliers.).  Thus, these data again suggest that exchange increases proportionally with FosX
preference for metal cofactor.  The rapid exchange for this peptide is contrary to our
sample peptide A1 (D) k 1  (min-1) A2 (D) k 2  (min-1)
Native 110-116 2.4 ± 0.3 0.17 ± 0.05 3.4 ± 0.3 (1.7 ± 0.8) x 10-3
Mn2+ 2.8 ± 0.3 0.25 ± 0.09 0.8 ± 0.3 0.002 ± 0.002
Co2+ 3.4 ± 0.4 0.3 ± 0.1 1.4 ± 0.3 0.004 ± 0.002
Zn2+ 2.9 ± 0.3 0.11 ± 0.05 2.5 ± 0.4 (2.5 ± 0.8) x 10
-3
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expectations for a helical peptide, which by nature is a moderately rigid element of
secondary structure.
Figure 19.  HXMS backbone amide kinetic profile for peptide 125-133.
Table 7.  Rate constants and amplitudes for peptide 125-133.
FosX Dynamics at Regions Removed from Active Site
Though we often place little importance on regions of a protein that are not part of
the catalytic active site, data presented here suggest that these residues do in fact play a
role in catalysis despite their location several angstroms away from the activity center.
Peptide 11-21.  This peptide does not contain any metal binding or substrate recognition
sites, and it is the farthest away from the metal center than any other area of the protein.
Nevertheless, we continue to observe the Mn2+>Co2+>Zn2+≈native fast exchange trend
explained above (Figure 20).  Although the rate differences are not as pronounced in this
example, they are still statistically relevant (Table 8).  Constants for peptide 11-22 are also
displayed to show the reproducibility of the results gleaned from this technique.
Peptide 125-133 (8)
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125-133 apo
125-133 mn
125-133 co
125-133 zn
Time (min)
sample peptide A1 (D) k 1  (min-1) A2 (D) k 2  (min-1)
Native 125-133 4.0 ± 0.8 2.3 ± 0.5
Mn2+ 100% exchange @ 15 s
Co2+ 1.7 ± 0.6 2.2 ± 0.8
Zn2+ 1.10 ± 0.06 0.004 ± 0.001
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Figure 20.  HXMS backbone amide kinetic profile for peptide 11-21.
Table 8.  Rate constants and amplitudes for peptides 11-21 and 11-22.
Peptide 22-29.  This peptide covers the last few residues of the α-helix spanned by above
peptide 11-21, and the beginning of a large loop whose exact length is unknown due to
missing electron density in the crystal structure.  As is the case with 11-21, this peptide does
not contain any functionally significant residues and is removed from the active site, yet the
same exchange trend is observed.  The amide protons comprising this peptide exchange
significantly throughout the time course in the intermediate and slow phases, suggesting a
conformational change rather than heightened solvent accessibility.  Several peptides
spanning this area were isolated from the peptide mapping experiment and the HXMS
results from each are shown to convey reproducibility in Table 9.  The exchange plot for
peptide 22-29 is shown in Figure 21.
Peptide 11-21 (10)
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11-21 apo
11-21 Mn
11-21 Co
11-21 Zn
Time (min)
sample peptide A1 (D) k 1  (min-1) A2 (D) k 2  (min-1)
Native 11-21 6.1 ± 0.2 0.025 ± 0.003
Mn2+ 4.5 ± 0.2 0.043 ± 0.008
Co2+ 5.1 ± 0.2 0.032 ± 0.003
Zn2+ 5.8 ± 0.2 0.027 ± 0.003
Native 11-22 6.5 ± 0.3 0.015 ± 0.003
Mn2+ 4.3 ± 0.2 0.43 ± 0.008
Co2+ 4.8 ± 0.2 0.016 ± 0.003
Zn2+ 6.0 ± 0.3 0.019 ± 0.004
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Figure 21.  HXMS backbone amide kinetic profile for peptide 22-29.
Table 9.  Rate constants and amplitudes for peptides 22-26, 22-28, and 22-29.
Peptide 54-62.  The exchange results for this peptide are quite dramatic; the rates and
amplitudes for native enzyme, Co2+, and Zn2+ are virtually identical (they differ by <5%),
while exchange of FosX bound to Mn2+ is >20% higher.  This further demonstrates that a
global conformational change is somehow induced upon binding to the catalytically
preferred metal (Figure 22, Table 10).
Peptide 22-29 (7)
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22-29 apo
22-29 Mn
22-29 Co
22-29 zn
Time (min)
sample peptide A1 (D) k 1  (min-1) A2 (D) k 2  (min-1)
Native 22-26 3.83 ± 0.06 (4.8 ± 0.4) x 10-3
Mn2+ 2.9 ± 0.1 0.009 ± 0.002
Co2+ 3.08 ± 0.06 (3.5 ± 0.4) x 10-3
Zn2+ 3.80 ± 0.06 (3.5 ± 0.3) x 10-3
Native 22-28 3.5 ± 0.1 0.31 ± 0.09 2.0 ± 0.2 (5.0 ± 0.6) x 10-3
Mn2+ 1.9 ± 0.2 0.12 ± 0.03 1.4 ± 0.2 (2.6 ± 0.9) x 10-3
Co2+ 1.7 ± 0.3 0.5 ± 0.2 2.3 ± 0.2 0.005 ± 0.001
Zn2+ 3.6 ± 0.2 0.20 ± 0.07 2.2 ± 0.2 (4.4 ± 0.7) x 10-3
Native 22-29 2.7 ± 0.2 0.26 ± 0.06 3.6 ± 0.2 (4.8 ± 0.6) x 10-3
Mn2+ 2.4 ± 0.3 0.3 ± 0.1 2.0 ± 0.2 0.005 ± 0.001
Co2+ 2.5 ± 0.3 0.12 ± 0.04 2.5 ± 0.3 0.003 ± 0.001
Zn2+ 2.9 ± 0.4 0.13 ± 0.05 3.3 ± 0.4 0.004 ± 0.001
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Peptide 54-62 (8)
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Time (min)
Figure 22.  HXMS backbone amide kinetic profile for peptide 54-62.
Table 10.  Rate constants and amplitudes for peptide 54-62.
Exchange Near Catalytic Base E44 Reveals Novel Mechanism
Perhaps the most striking observations from these experiments concern the
structural fluctuations that occur at and around residue E44, which is the general base
responsible for adding water to the oxirane carbon of fosfomycin.  Previous work has shown
that mutating this residue to glycine completely abolishes FosX activity (24).  Data in this
section indicate that increased dynamic motion around this site is necessary to enable
fosfomycin hydrolysis and appears to be a function of which metal cofactor is bound to
protein.
Peptides 40-46 and 42-46 containing E44.  Like peptides 1-10 and 1-5 discussed earlier,
observing the exchange rates for overlapping peptides permits enhanced spatial resolution,
and in this case gives us a better idea of the dynamics near critical residue E44 than can be
afforded by either peptide alone.  Analysis of exchange rates for peptide 40-46 shows that
sample peptide A1 (D) k 1  (min-1) A2 (D) k 2  (min-1)
Native 54-62 3.7 ± 0.1 0.10 ± 0.02 1.6 ± 0.1 (1.8 ± 0.2) x 10-3
Mn2+ 1.3 ± 0.2 0.6 ± 0.2 2.3 ± 0.2 0.034 ± 0.004
Co2+ 3.2 ± 0.1 0.09 ± 0.02 1.8 ± 0.1 (1.8 ± 0.2) x 10-3
Zn2+ 3.7 ± 0.2 0.07 ± 0.03 1.4 ± 0.2 (1.8 ± 0.4) x 10
-3
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the profiles are very similar; rapid exchange by the first time point is approximately 40% for
all species (Figure 23 left, Table 11).  However, for peptide 42-46, we see that while there is
no exchange by 15 s for native and Co2+-bound enzyme, exchange with bound Mn2+ is 40%
complete (Figure 23 right, Table 11).
Figure 23.  HXMS backbone amide kinetic profiles for peptides 40-46 (left) and 42-46
(right).
Table 11.  Rate constants and amplitudes for peptides 40-46 and 42-46.
Peptide 45-47.  The most significant change in dynamics across the entire protein is seen in
this short peptide adjacent to residue E44.  Fast exchange with bound Mn2+ is 50% greater
than that of native, Co2+-bound, or Zn2+-bound enzyme (rates of these three differ by <5%).
This peptide is also interesting because the only species experiencing full exchange of both
deuterons is Mn2+-bound FosX; the other three species appear to exchange only one
hydrogen for deuterium.  The HXMS data shown in Figure 24 and Table 12 demonstrate
that a conformational change dependent on metal ion is occurring at this peptide.  A
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Peptide 42-46 (4)
42-46 apo
42-46 Mn
42-46 Co
Time (min)
sample peptide A1 (D) k 1  (min-1) A2 (D) k 2  (min-1)
Native 40-46 1.6 ± 0.4 1.3 ± 0.5 2.5 ± 0.1 0.009 ± 0.001
Mn2+ 2.3 ± 0.2 0.20 ± 0.06 0.8 ± 0.2 0.005 ± 0.003
Co2+ 1.7 ± 0.8 0.12 ± 0.11 1.6 ± 0.8 0.006 ± 0.006
Zn2+ 1.4 ± 0.5 1.2 ± 0.8 2.7 ± 0.2 0.009 ± 0.002
Native 42-46 1.3 ± 0.3 0.8 ± 0.4 2.6 ± 0.1 0.007 ± 0.001
Mn2+ 0.5 ± 0.1 0.18 ± 0.04 2.0 ± 0.1 0.004 ± 0.003
Co2+ 3.0 ± 0.4 1.7 ± 1.5 1.9 ± 1.1 0.014 ± 0.005
Zn2+
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possible reason for this observation is that this region of the protein forms a channel to allow
approach of the catalytic water molecule; this would explain why the fast exchange trend
always proceeds from most preferred metal to least preferred metal.  A more detailed
discussion of this theory follows in the proceeding section.
Figure 24.  HXMS backbone amide kinetic profiles for peptide 45-47.
Table 12.  Rate constants and amplitudes for peptides 40-46 and 42-46.
Summary of HXMS data
The color-coded ribbon diagrams showing the fast exchange percentages for native,
Mn2+-bound, Co2+-bound, and Zn2+-bound enzyme are shown below in Figure 25.
Examination of these structures emphasizes that the act of binding Mn2+ increases solvent
accessibility throughout the protein, as indicated by the abundance of red segments
(indicating >80% fast exchange).  The Co2+ structure can be regarded as an exchange
intermediate, lying between the abundant fast exchange of the Mn2+ structure and the
minimal fast exchange of the Zn2+ and apoenzyme structures.  As only very small
percentages separate the exchange rates of Zn2+ and apoenzyme, these structures appear
sample peptide A1 (D) k 1  (min-1) A2 (D) k 2  (min-1)
Native 45-47 1.85 ± 0.03 (1.1 ± 0.2) x 10-3
Mn2+ 0.82 ± 0.08 0.08 ± 0.03
Co2+ 0.7 ± 0.2 2.2 ± 0.9 1.20 ± 0.03 (1.5 ± 0.02) x 10-3
Zn2+ 1.91 ± 0.05 (1.4 ± 0.3) x 10
-3
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virtually identical.  The exchange rates for these species follow the previously observed
trend in Listeria monocytogenes Fos X metal preference: Mn2+>Co2+>>Zn2+≈apo.
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Figure 25.  Ribbon diagrams illustrating fast exchange percentages for certain peptides
selected to maximize protein coverage  (clockwise from top left: native, Mn2+-bound, Zn2+-
bound, Co2+-bound).
<20 31-40 41-50 51-60 61-70 71-80 >8021-30 % fast exchange
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Discussion
The results presented above demonstrate that the level of fast exchange, reflective
of solvent accessibility and/or structural perturbations, peaks upon binding the preferred
metal cation Mn2+.  As catalytic activity decreases with binding to less preferred metals, the
exchange rates begin to more closely resemble those of the native enzyme.  To verify that
Mn2+ is not acting as a Lewis base to catalyze exchange, the distances between each
backbone amide nitrogen and the nearest Mn2+ cation were measured.  Appendix C shows
that the rate does not depend on the distance from the metal.  Although these experiments
cannot determine the reason for this exchange phenomenon, examples in the literature can
perhaps shed some light on this behavior and suggest future experiments to uncover the
mechanism.
The protein Troponin C (TnC) is a Ca2+-binding protein involved in regulating muscle
contraction.  When Ca2+ binds the protein, a conformational change signals neighboring
protein Troponin I (TnI) to initiate a cascade of structural changes that ultimately results in
contraction of the muscle.  An H/D exchange NMR experiment probing the solution
dynamics of TnC reveals that when the protein binds to Ca2+, the structure undergoes a
conformational opening whereby a hydrophobic patch necessary for binding TnI is exposed.
NMR spectra reveal that both of the regulatory Ca2+ binding sites experience an increase in
deuterium incorporation by several deuterons.  Most of the protein shows faster exchange
after binding metal, while the first approximately 30 residues maintain the same level of
exchange as native TnC (41). Likening this example to FosX, it is possible that the FosX
structure must open or partially unfold in such a way as to expose the fosfomycin binding
site.  (We have previously shown that FosX binding is ordered, with metal preceding
fosfomycin.)  This structural opening would be most stimulated by the most catalytically
relevant metals, explaining why the dynamics are so much greater for Mn2+, followed by
Co2+ and finally Zn2+.
Another example concerns β 2-microglobulin, a component of the major
histocompatibility complex I that can form amyloid fibrils and aggregate in bone and joint
tissue.  Experiments show that Cu2+ increases dynamics throughout the protein and
especially at the four metal binding residues.  This conformational motion caused by Cu2+ is
thought to be responsible for amyloid formation and does not occur in the presence of other
divalent metals.  To explain their findings, the authors state their theory that the binding of
Cu2+ leads to a destabilization of the protein’s native state that exhibits decreased stability
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and increased flexibility.  The shift to a destabilized state spreads cooperatively throughout
the protein as hydrogen bonds and hydrophobic interactions are weakened, thus translating
into a global increase in protein dynamics (42).
The idea of a partially folded FosX intermediate recalls the concept of protein folding
“energy funnels.”  The current view of the protein folding problem is that there is no specific
route by which a protein adopts its native conformation; rather, it can occur in many different
ways, three of which are illustrated and explained below (Figure 26).  In all of these
hypothetical energy landscapes, a particular event is necessary to propel the protein over an
energy barrier so that it can reach its native conformation.  Until this event occurs, the
protein is constantly in motion, in some cases adopting a higher entropy structure until it can
“find its way downhill” to the bottom of the energy funnel (43).  In the case of FosX, it may be
that the binding of Mn2+ shifts the protein into a partially unfolded or destabilized native state
with higher entropy than the native structure.  This can be viewed as one of the kinetic traps
on an energy funnel.  Perhaps the binding of fosfomycin initiates stabilization and refolding,
allowing the entropy and the free energy to decrease.
Figure 26.  Protein folding landscapes, illustrating the complex paths a protein can take
before arriving at its lowest energy state.  Multiple routes are possible.
Another possible explanation for increased exchange with bound Mn2+ that does not
concern protein folding can be illustrated by the behavior of peptides 42-46 and 45-47.
Again, peptide 45-47 experiences the largest fast exchange percentage increase of any
other peptide.  Perhaps before FosX binds to metal, hydrogen bonding forces within the
protein and interactions with ordered waters surrounding the protein are strong, thereby
decreasing the overall flexibility of the structure.  Then when the metal binds, the water
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molecules become more disordered and their interactions with the backbone weaken to
increase overall flexibility, allowing for the approach of the mechanistic water molecule and
fosfomycin through a channel to the active site (44).  This would explain why we see
increased motion when Mn2+ binds as opposed to Co2+ or Zn2+; since Mn2+ confers the
highest catalytic activity, its binding to FosX induces a change in motion, particularly near
residues 42-47, that allows the water molecule to readily approach the active site where E44
will abstract a proton.  The channel created by Co2+ is not as large, so the water cannot
approach or orient itself as quickly as it can for Mn2+.  It follows that Zn2+, which is a very
poor catalytic metal, would be ineffective at producing this channel and as a result we
observe dynamic motions characteristic to native protein.
Since the FosX peptic maps for two other acid proteases are complete, HXMS
experiments should be performed using these proteases to verify the results we have
collected and to enhance spatial resolution.  Other metals should be tried as well to
determine how the exchange rates relate to FosX preference for the metal.  The preference
scale is as follows: Mn2+>>Ni2+>>Fe2+>Co2+>Mg2+≈Ca2+>>Zn2+ (unpublished observations).
It would also be beneficial to perform HXMS experiments on protein/metal/fosfomycin and
protein/metal/diol product complexes; observing a decrease in exchange rates would
substantiate the theory that Mn2+ binding results in a partially folded intermediate or
destabilized native state of FosX whose entropy is lessened by binding to fosfomycin.
To investigate the protein folding issue, a pulsed quench HXMS experiment can be
conducted using a stopped-flow apparatus.  The concept underlying the experiment is very
similar to canonical HXMS except that pulsed quench investigates protein dynamics on a
much smaller time scale.  The protein is incubated with D2O and a denaturant to promote
unfolding, and the sample is then rapidly diluted in H2O to initiate the refolding process and
catalyze exchange of D for H.  In this sense, this procedure is backwards from standard
HXMS, since pulsed quench will measure a decrease in mass. The refolding period is
analogous to the protein/D2O incubations in canonical HXMS, because in both procedures
the protein is quenched at particular time points (45).  From this experiment, we would be
able to compare folding of the protein/metal complex with the protein/metal/fosfomycin
complex.  If we detect slower folding without fosfomycin, we can conclude that the protein
structure is more disordered with bound metal, and that fosfomycin binding may stabilize the
structure so catalysis can occur.
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CHAPTER V
INVESTIGATIONS INTO LISTERIA MONOCYTOGENES FOSX
STEADY STATE METAL BINDING
Results
The main reason for performing these binding experiments was to determine the
number of metal equivalents needed to fully saturate the binding sites of FosX for the HXMS
experiments, since incubation with an excess of metal resulted in high signal to noise and
impossible peptide mass analysis in many cases.  Metal excess was initially used when
performing HXMS because we hypothesized that a possible reason for the lower catalytic
rates with certain metals was due to ineffective binding.  As a result, we incubated the
protein with as many as five equivalents of metal in some cases.  The following
spectroscopic experiments were designed to clarify the binding saturation of FosX with its
metal ion cofactors so that we could later obtain the best signal to noise possible in HXMS
while still ensuring that we were capturing a realistic picture of the protein/metal structure
dynamics.
Co2+ was chosen for absorbance experiments because of its strong spectroscopic
signal, and based on the knowledge that it does supply catalytic activity, albeit modest, to
FosX.    The plot in Figure 27 displays the entire absorbance spectrum for the titration of
Co2+ into a predetermined concentration of protein. Binding saturation was monitored by
calculating the absorbance difference between 470 nm and 424 nm, since the peak height
was observed to level off in a series of preliminary experiments.  No other selected
wavelength(s) yielded an interpretable data set, so we believe this range is an ideal reporter
of metal binding.  The data in Figure 28 were obtained by correcting these absorbance
values for background and dilution and plotting them versus concentration to determine the
number of Co2+ equivalents needed to saturate FosX binding sites.  Data points plateau at
one equivalent [Co2+]:[FosX], consistent with our original assumption that binding is
stoichiometric.  From this observation, adding one equivalent of Co2+ to FosX for HXMS
binding experiments is necessary and sufficient to obtain an accurate profile of Co2+-bound
protein.
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Figure 27.  Ligand field envelope region of absorption spectra collected as increasing
amounts of Co2+ (0-400 uM) were titrated into protein sample (200 uM).
Figure 28.  FosX absorbance saturation with Co2+ as a function of the ratio [Co2+]:[FosX].
Absorbance reported is the result of difference spectroscopy between 470 and 424 nm.
Competition experiments whereby Mn2+ and Zn2+ were used to displace bound Co2+
were used to assess binding properties of these two metals, because they are
spectroscopically silent.  Unfortunately, results were inconclusive using the absorbance
technique (data not shown).  As a result, fluorescence was used as an alternate technique
and proved to be very effective.  First, the Co2+ titration experiment was repeated to verify
that the number of saturating equivalents obtained was equal to the absorbance results.
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Figure 29 shows that results produced are virtually identical, with a fluorescence plateau at
approximately one equivalent. [Co2+]:[FosX].  The segment leading up to the plateau is
linear, permitting curve fitting analysis with a 1:1 binding model to determine KD.  Such an
analysis cannot performed here, however, because a metal chelator is not present (more on
this topic in Discussion).
Figure 29.  FosX fluorescence saturation with Co2+ as a function of the ratio [Co2+]:[FosX].
Fluorescence reported is the result of difference spectroscopy between 470 and 424 nm.
An identical experiment to the one above with Co2+ was conducted to determine the
binding stoichiometry of preferred metal Mn2+.  The fluorescence plot shown in Figure 30
reveals that although the data points appear to level off around 1-1.5 equivalents
[Mn2+]:[FosX], the shape of the curves are very different from those resulting from Co2+
binding.  The segment leading to the approximate plateau is surely not linear as we saw with
Co2+; instead, it is best fit to a sigmoidal curve, implying that binding to this metal occurs in a
different fashion than to Co2+.  Details on possible reasons for the shape observed here
follow in the discussion section.  What we can deduce, however, is that one equivalent
[Mn2+]:[FosX] should suffice for binding saturation in HXMS experiments.
The Zn2+ competition experiment with Co2+ also yields an approximately
stoichiometric saturation value of one equivalent [Zn2+]:[FosX] (Figure 31).  Because the
points preceding the plateau point connect in a linear fashion as was the case with Co2+, the
data can be fit to a 1:1 binding model under the proper conditions explained in the next
section.
These experiments reveal that binding of Mn2+, Co2+, and Zn2+ to FosX occurs in
stoichiometric fashion, permitting HXMS evaluation to be performed with only one equivalent
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of metal in the incubation step.  However, the dissimilar curve shapes among these metals
indicate that the cofactors may have different protein binding mechanisms.
Figure 30.  FosX fluorescence saturation with Mn2+ as a function of the ratio [Mn2+]:[FosX].
Fluorescence reported is the result of difference spectroscopy between 470 and 424 nm.
Figure 31.  FosX fluorescence saturation with Zn2+ as a function of the ratio [Zn2+]:[FosX].
Fluorescence reported is the result of difference spectroscopy between 470 and 424 nm.
Discussion
Although the Co2+ titration experiment produced data points that can be extrapolated
to a 1:1 binding equation, the KD yielded from such an analysis would be merely an upper
limit, since these experiments were performed with an excess of metal.  The upper limit KD
derived with extrapolation from the above Co2+ plot is 0.33 µM.  For the most accurate
determination of dissociation constants for each metal, however, a chelator should be
present in a higher concentration than the metal so as to buffer the amount of free metal in
solution.  A common chelator used for this purpose is EGTA (39, 40).  An accurate KD for
each metal can be obtained in the future using this technique.
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The reason for the sigmoidal shape of the Mn2+ titration curve is unknown at this
point.  A possible explanation is that the cuvette contained a competing metal species,
either from inadequate acid soaking of the cuvette to remove contaminants or from a metal
other than Mn2+ being present in the Mn2+ stock used in the titration.  This experiment should
be repeated with a new Mn2+ stock to determine if metal contamination is the problem.
Another possibility is that the metal/protein solution did not sufficiently equilibrate.
Incubation times greater than ten minutes may lead to increased linear character of the data
points.  However, the likelihood remains that the sigmoidal shape of this curve is due to a
complex binding mechanism between Mn2+ and FosX.
Figure 32 displays the superposition of the fluorescence titration data points for Mn2+
and Zn2+ and emphasizes that the shapes, as well as the fluorescence values themselves,
are indeed very different.  The fact that the plateaus do not occur at the same point along
the y-axis implies that the protein fluoresces differently when bound to one metal versus
another, and could be related to the differences in amide hydrogen observed for each metal.
Further insights into the binding mechanisms of these metals cannot be determined from
these studies, but future work including stopped-flow experiments would help to elucidate
pre-steady state information. Since steady state kinetics represent a composite calculation
of several microscopic rate constants, understanding the pre-steady state rates that make
up the kcat and KM values will provide additional valuable information about the FosX
reaction.
Figure 32.  Superposition of Mn2+ and Zn2+ fluorescence titration data.
[M2+]/
[FosX
]
[M2+]/[FosX]
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CHAPTER VI
CHARACTERIZATION OF A NOVEL FOSX ENZYME FROM THE
PSEUDOMONAS PUTIDA GENOME
Results
Expression and Purification of Pseudomonas putida FosX
Because of the high purity of protein yield afforded by the cation exchange SP
Sepharose column, only one column was needed for purification of the putative FosX
enzyme (Figure 33).  Final yield was 25 mg/L of protein.  Actual molecular weight of
16150.18 Da as deduced from MALDI-MS spectrum (Figure 34) agrees with the theoretical
value of 16,150 Da.
Figure 33.  Purification gel with arrow marking the position of Pseudomonas putida FosX.
Lane 1 is initial column flow-through.
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Figure 34.  MALDI mass spectrum of Pseudomonas putida FosX at molecular weight of
16150 Da.
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Determination of Minimum Inhibitory Concentration of Fosfomycin
Discovery of this protein's ability to confer fosfomycin resistance to E. coli cells will
allow us to classify the enzyme as a true FosX.  In order to provide a basis for comparison,
cell growth was compared to cells that had been transformed with the robust Listeria
monocytogenes FosX, whose fosfomycin MIC value has been established as >25 mg/mL.
Resistance values above this cannot be accurately determined due to fosfomycin solubility.
Empty pET20b(+) vector was also transformed into cells as a control and should be
susceptible to fosfomycin treatment.  MIC values, or the fosfomycin concentration at which
bacterial no longer survive, are assessed by visually inspecting the plates or liquid cultures;
thus the higher the value, the more resistance the enzyme confers.
Figure 35 shows the results of the plated cell growth assays.  The P. putida enzyme
clearly confers robust resistance to fosfomycin, since even in the presence of 20 mg/mL of
the antibiotic, a lawn of bacterial colonies survive and appear to be healthier than those
containing the gene from Listeria, which to this point has been regarded as the most
resistant of all the FosX enzymes.  Although the Listeria MIC value has been defined as >25
mg/mL, results shown here indicate that even though the colonies do survive, the number
and size of the colonies diminish with increasing concentrations of fosfomycin.
A reason for the better health of Pseudomonas versus Listeria colonies on these
plates is unclear at this time, since all cells were grown to an OD600 of 0.015 and plated
simultaneously.  The abundance and largeness of the Pseudomonas FosX-expressing
colonies were reproducible across several experiments.  Cells containing empty vector or
FosX gene inserts were grown in small cultures according to their established expression
protocols, so that expression of each would be as high as possible.  As expected, the empty
vector control showed complete obliteration of cell growth at fosfomycin concentrations
greater than 0 mg/mL.
To ensure that the observed results were not due to experimental error (since it is
rare for us to see such heightened resistance in FosX enzymes other than the one from
Listeria), a similar experiment was performed in liquid culture media.  Growth was assessed
by measuring the OD600 of cell cultures that had been treated with 0-20 mg/mL fosfomycin,
and FosA inhibitors PF and AcP were added to 20 mg/mL fosfomycin cultures to determine
if cell density increased.  Table 13 shows that regardless of fosfomycin or FosA inhibitor
concentration, cell growth is almost identical in all conditions except 100 uM AcP, which may
indicate that this compound inhibits FosX activity at high concentrations.  However, AcP
inhibition was not observed in 31P-NMR experiments (data not shown), so the observation
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may simply be due to an unhealthy cell culture.  The liquid culture assays were performed
twice and should be repeated to verify results.
From the MIC experiments, we conclude that the enzyme confers robust resistance
in the biological context of E. coli, rivaling even the MIC values for Listeria, which thus far
had been the most fosfomycin-resistant FosX.
Figure 35.  Growth of E. coli cells expressing P. putida and L. monocytogenes FosX as well
as empty vector control.  Clockwise from top left: 0 mg/mL, 5 mg/mL, 20 mg/mL, 10 mg/mL
fosfomycin.
L.m
.
P.p
.
pEt20
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Table 13.  Liquid culture growth in cells expressing P. putida FosX.  Left: 4-hr growth with
different fosfomycin concentrations.  Right: 4- and 7-hr growth in 20 mg/mL fosfomycin with
different inhibitor concentrations.
Catalytic Properties Deduced from 31P-NMR Spectroscopy
Interestingly, NMR results do not corroborate the in vivo resistance that we observe
in the previous section; in fact, the enzyme appears to be a very poor catalyst.  The enzyme
was incubated with a variety of divalent metals to determine with which it exhibits the
highest catalytic activity.  FosX enzymes characterized to date have displayed the highest
turnover rates with either Mn2+ or Cu2+, and preferences for the remaining metals vary
depending on the enzyme (unpublished observations).  Optimum reaction times were
determined experimentally and are defined as the period during which 10-15% product
conversion is observed; 19 hours reaction time are required to observe this product
turnover, which implies that this enzyme performs the FosX reaction at an extremely low
rate.  The metal preference of the Pseudomonas FosX is Mn2+ > Ni2+ > Mg2+ > Cu2+ > Ca2+
(Figure 36).  No activity is observed for Co2+, Zn2+, Fe2+, or the no metal control (data not
shown).  The only metals with which we observe the proper turnover to allow rate
determination at pH 7.5 are Mn2+, Ni2+, and Mg2+; the kcat values are 0.024 s
-1, 0.015 s-1, and
0.010 s-1, respectively.
mg/mL fosfomycin OD600 (4 hrs)
0 2.3
0.05 2.08
0.1 1.82
0.5 1.98
2 1.39
10 1.52
[inhibitor] OD600 (4 hrs)OD600 (7 hrs)
none 0.32 1.1
10uM Pf 0.23 1.15
50uM Pf 0.21 1.09
100uM Pf 0.26 1.07
10uM AcP 0.24 1.1
50uM AcP 0.25 1.05
100uM AcP 0.08 0.8
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Figure 36.  31P-NMR spectra showing metal preferences of Pseudomonas putida FosX
reaction at pH 7.5, 19-hour incubation.  In preference order from left to right, top to bottom:
Mn2+, Ni2+, Mg2+, Cu2+, Ca2+.
However, a puzzling phenomenon occurs when the reactions are carried out at pH
9.5--the rates dramatically increase.  Figure 37 shows the pH profile of FosX reactions
incubated for 19 hours.  To determine turnover rates, all conditions were kept the same
except incubation times were reduced to 2 hours.  Significant rate improvement is observed
only for the top two preferred metals Mn2+ (15-fold increase to 0.35 s-1) and Ni2+ (5-fold
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increase to 0.076 s-1).  To determine whether this high optimum pH is characteristic of the
Listeria enzyme as well,  NMR experiments were carried out according to the same
procedure.  Turnover at pH 9.5 is improved only 1.05-fold over pH 7.5, not an appreciable
difference (data not shown).
Figure 37.  31P-NMR spectra showing pH profile of Pseudomonas putida FosX reaction with
19-hour incubation.  From left: pH 5.5, 6.5, 7.5, 8.5, and 9.5.
The enzyme does not show any catalytic activity whatsoever when GSH or L-cys are
used as substrates for the FosA and FosB reactions, respectively, nor is the FosX activity
affected by adding FosA inhibitors Pf or AcP (Figure 38).  These reactions were tested at
variable substrate and inhibitor concentrations to guard against the possibility of substrate
inhibition.
                   Phosphonoformate (PF)          Acetylphosphonate (AcP)
Figure 38.  Structures of FosA inhibitors Phosphonoformate (PF) and Acetylphosphonate
(AcP).
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Discussion
Clearly, we must resolve the discrepancy between the in vitro NMR results, showing
that the enzyme has very low catalytic activity, and the in vivo results, showing that the
enzyme confers robust resistance to fosfomycin when expressed in E. coli.  The NMR data
shows that FosX activity is nominal, and since the only peaks on the spectra are fosfomycin
and its hydrolyzed product, this implies that the only alteration of the fosfomycin molecule is
conversion to diol.  At least when the only reactants are enzyme, fosfomycin, and metal
cofactor, the only enzymatic reaction is hydrolysis.
However, we observe a very different outcome when the enzyme is overexpressed in
E. coli; the robust resistance signifies that the bacteria are somehow consuming and
inactivating fosfomycin. From these observations, we must conclude that this enzyme is
capable of an alternate activity that is undetectable by 31P-NMR.  Several examples in the
literature may  help to clarify this incongruity.
The related species Pseudomonas fluorescens encodes a phosphonoacetate
hydrolase gene (phnA) capable of cleaving the carbon-phosphorus bond of substrates
phosphonoacetate (PA) and 2-phosphonopropionate (2PP) (Figure 39).  Interestingly,
analysis revealed that the substrate is necessary to induce the gene required for substrate
utilization.  When the gene was subcloned into E. coli and P. putida host strains, hydrolase
activity was not detected unless a second gene phnR, located upstream of phnA in P.
fluorescens, was also subcloned.  In this way, phnR acts as a transcriptional regulator.  This
activity represents the only known example of a C-P cleavage enzyme not under control of
the pho operon (46).
                   Phosphonoacetate (PA)        2-Phosphonopropionate (2PP)
Figure 39.  Structures of potential FosX substrates Phosphonoacetate (PA) and 2-
Phosphonopropionate (2PP).
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The novel properties of this phosphate hydrolase gene lend some insight into the
hydrolase enzyme found in P. putida.  Perhaps on the P. putida integron encoding FosX,
one of the uncharacterized ORFs acts as a transcriptional regulator in much the same way
as the above example; if so, the enzyme has very little or no activity without the second
gene.  Without the additional gene product being present in our NMR experiments, the FosX
is only slight.  However, when the gene encoding the P. putida FosX is expressed in E. coli,
perhaps a similar regulator to the one in P. putida is present in the E. coli genome, serves
as an inducer, and thereby allows the enzyme to confer resistance.  In other words, the
gene’s activity can only be “turned on” in the cell but cannot be simulated in in vitro assays.
To test this possibility, the other enzymes encoded on the P. putida integron can be
engineered into the plasmid containing FosX and activity then assessed.  Substrates PA
and 2PP, whose structures bear similarity to fosfomycin, would also be worthwhile to test as
potential FosX substrates.
A related explanation for these peculiar results could be that the unknown product is
somehow utilized by another enzyme in vivo which allows resistance to occur in E. coli cells
but not in the NMR experiment.  The above example describes a reaction in which the C-P
bond is cleaved, a mechanism different from the FosX ring-opening reaction that cleaves a
C-O bond.  Perhaps the P. putida enzyme also catalyzes a C-P bond breakage, and the
resulting reaction product can then act as a substrate for a second enzyme—possibly a
transporter protein that shuttles the molecule outside the cell.  Immunoprecipitation assays
can be used to determine if a second protein interacts with the FosX in vivo.  To test for C-P
bond breakage activity, a procedure can be used to measure inorganic phosphate release.
Alternatively, maybe the reaction product is used as a nutrient phosphate source.
Several years ago, a paper illustrated that P. putida cultures grew when incubated
separately with phosphonates 2-aminoethylphosphonic acid (AEP) and methylphosphonic
acid (MPA) (Figure 40) (47).  Maybe the P. putida enzyme somehow generates one of these
products and then uses it for nutrition.  This seems likely, because another paper reported
robust P. putida growth when cultures were incubated with fosfomycin but without other
phosphorus or carbon sources (48).  Of course, if this scenario is correct, there still must be
a missing cofactor, because otherwise a free phosphate peak would appear on NMR
spectra.
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    2-Aminoethylphosphonic acid (AEP)         Methylphosphonic acid (MP)
Figure 40.  Structures of potential FosX substrates 2-Aminoethylphosphonic acid (AEP) and
Methylphosphonic acid (MP).
The possibility still remains that our in vitro assay simply does not contain the metal
cofactor necessary for optimum activity.  Future experiments could include metals with
charges of +1, +3, or +4.  Crystallography structures in the presence of a catalytically
relevant metal would greatly aid our understanding of this enzyme, because they may
indicate what residues are responsible for the heightened catalytic activity at increasingly
basic pH. But considering these many potential reasons for the lack of NMR activity, the
best way to determine the role of this enzyme is still to study it in its native context, the
organism Pseudomonas putida.  This species is known for its incredible ability to deactivate
countless compounds in the soil, so it makes sense that it would develop a mechanism to
degrade and utilize fosfomycin to its advantage.  Assuring that strict safety precautions are
followed, perhaps the laboratory can one day determine how this enzyme confers resistance
by investigating the bacterium directly.
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APPENDIX
LISTERIA MONOCYTOGENES PEPTIDE MAPS GENERATED BY PROTEOLYTIC
 CLEAVAGE WITH PEPSIN, ASPERGILLUS SAITOI PROTEASE XIII, AND RHIZOPUS
PROTEASE XVIII
PEPSIN
85% Coverage
M  I  S  G  L  S  H  I  T  L  I  V  K  D  L  N  K  T  T  A
F  L  Q  N  I  F  N  A  E  E  I  Y  S  S  G  D  K  T  F  S
L  S  K  E  K  F  F  L  I  A  G  L  W  I  C  I  M  E  G  D
S  L  Q  E  R  T  Y  N  H  I  A  F  Q  I  Q  S  E  E  V  D
E  Y  T  E  R  I  K  A  L  G  V  E  M  K  P  E  R  P  R  V
Q  G  E  G  R  S  I  Y  F  Y  D  F  D  N  H  L  F  E  L  H
A  G  T  L  E  E  R  L  K  R  Y  H  E
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ASPERGILLUS SAITOI PROTEASE XIII
78% Coverage
RHIZOPUS PROTEASE XVIII
69% Coverage
M  I  S  G  L  S  H  I  T  L  I  V  K  D  L  N  K  T  T  A
F  L  Q  N  I  F  N  A  E  E  I  Y  S  S  G  D  K  T  F  S
L  S  K  E  K  F  F  L  I  A  G  L  W  I  C  I  M  E  G  D
S  L  Q  E  R  T  Y  N  H  I  A  F  Q  I  Q  S  E  E  V  D
E  Y  T  E  R  I  K  A  L  G  V  E  M  K  P  E  R  P  R  V
Q  G  E  G  R  S  I  Y  F  Y  D  F  D  N  H  L  F  E  L  H
A  G  T  L  E  E  R  L  K  R  Y  H  E
M  I  S  G  L  S  H  I  T  L  I  V  K  D  L  N  K  T  T  A
F  L  Q  N  I  F  N  A  E  E  I  Y  S  S  G  D  K  T  F  S
L  S  K  E  K  F  F  L  I  A  G  L  W  I  C  I  M  E  G  D
S  L  Q  E  R  T  Y  N  H  I  A  F  Q  I  Q  S  E  E  V  D
E  Y  T  E  R  I  K  A  L  G  V  E  M  K  P  E  R  P  R  V
Q  G  E  G  R  S  I  Y  F  Y  D  F  D  N  H  L  F  E  L  H
A  G  T  L  E  E  R  L  K  R  Y  H  E
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ALL HYDROGEN/DEUTERIUM EXCHANGE MASS SPECTROMETRY PLOTS,
SHOWN INDIVIDUALLY WITH GOODNESS OF FIT DATA
Black: native
Red: Mn2+-bound
Blue: Co2+-bound
Green: Zn2+-bound
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     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
11-22 (11)
4.831
0.01614
0.2376
0.003173
4.314 to 5.349
0.009230 to 0.02306
12
0.8804
4.137
0.5872
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 11-22 (11)
0.1 1 10 100 1000
0
2
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8
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12
11-22 (11)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
11-22 (11)
5.965
0.01927
0.3050
0.003805
5.300 to 6.629
0.01098 to 0.02756
12
0.8830
6.555
0.7391
A1 > 0.0
K1 > 0.0
14
1
Time (min)
67
Peptide 21-26 (5)
0.1 1 10 100 1000
0
1
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4
5
21-26 (5)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
21-26 (5)
1.365
0.09737
2.336
0.001644
0.1385
0.02806
0.1296
0.0003500
1.057 to 1.674
0.03485 to 0.1599
2.047 to 2.625
0.0008642 to 0.002424
10
0.9761
0.2174
0.1475
Time (min)
Peptide 21-26 (5)
0.1 1 10 100 1000
0
1
2
3
4
5
21-26 (5)
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
     Total number of values
     Number of missing values
4.368
0.001566
0.07901
0.0002149
4.196 to 4.540
0.001098 to 0.002034
12
0.8542
0.7107
0.2434
A1 > 0.0
K1 > 0.0
14
1
14
0
Time (min)
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Peptide 21-26 (5)
0.1 1 10 100 1000
0
1
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5
21-26 (5)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
21-26 (5)
4.437
0.001990
0.07297
0.0002894
4.277 to 4.598
0.001353 to 0.002627
11
0.8491
0.5133
0.2160
A1 > 0.0
K1 > 0.0
13
1
Time (min)
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Peptide 22-26 (4)
0.1 1 10 100 1000
0
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4 22-26 (4)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
22-26 (4)
3.826
0.004834
0.06483
0.0003960
3.684 to 3.967
0.003971 to 0.005697
12
0.9689
0.4126
0.1854
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 22-26 (4)
0.1 1 10 100 1000
0
1
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3
4 22-26 (4)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
22-26 (4)
2.940
0.009347
0.1242
0.001750
2.669 to 3.210
0.005535 to 0.01316
12
0.8771
1.287
0.3275
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 22-26 (4)
0.1 1 10 100 1000
0
1
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4 22-26 (4)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
22-26 (4)
3.077
0.003466
0.06023
0.0003534
2.946 to 3.208
0.002696 to 0.004236
12
0.9401
0.3785
0.1776
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 22-26 (4)
0.1 1 10 100 1000
0
1
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4 22-26 (4)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
22-26 (4)
3.801
0.003537
0.05519
0.0002660
3.681 to 3.921
0.002957 to 0.004116
12
0.9672
0.3169
0.1625
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 22-28 (6)
0.1 1 10 100 1000
0
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6
22-28 (6)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
22-28 (6)
1.949
0.1220
1.408
0.002619
0.1813
0.03284
0.1674
0.0009284
1.545 to 2.353
0.04881 to 0.1952
1.035 to 1.781
0.0005503 to 0.004687
10
0.9731
0.3701
0.1924
Time (min)
Peptide 22-28 (6)
0.1 1 10 100 1000
0
1
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4
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6
22-28 (6)
Time (min)
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
1.976
0.3145
3.533
0.005012
0.1934
0.09070
0.1439
0.0005765
1.545 to 2.407
0.1125 to 0.5166
3.212 to 3.854
0.003727 to 0.006296
10
0.9875
0.3770
0.1942
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Peptide 22-28 (6)
0.1 1 10 100 1000
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22-28 (6)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
22-28 (6)
3.609
0.004404
2.208
0.2002
0.2145
0.0006880
0.2425
0.06775
3.131 to 4.087
0.002871 to 0.005937
1.668 to 2.749
0.04921 to 0.3511
10
0.9819
0.6442
0.2538
Time (min)
Peptide 22-28 (6)
0.1 1 10 100 1000
0
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22-28 (6)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
22-28 (6)
1.748
0.4871
2.258
0.004831
0.2709
0.1957
0.1581
0.001040
1.144 to 2.351
0.05114 to 0.9230
1.906 to 2.611
0.002513 to 0.007149
10
0.9604
0.5883
0.2425
Time (min)
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Peptide 22-29 (7)
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22-29 (7)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
     A2
     K2
Data
22-29 (7)
2.668
0.2642
3.642
0.004830
0.2081
0.06305
0.1676
0.0006090
2.204 to 3.132
0.1237 to 0.4047
3.268 to 4.015
0.003473 to 0.006187
10
0.9891
0.4615
0.2148
A1 > 0.0
K1 > 0.0
A2 > 0.0
K2 > 0.0
Time (min)
Peptide 22-29 (7)
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22-29 (7)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
     A2
     K2
Data
22-29 (7)
2.403
0.2988
2.042
0.005147
0.2603
0.09628
0.2004
0.001396
1.823 to 2.983
0.08426 to 0.5133
1.596 to 2.489
0.002036 to 0.008258
10
0.9700
0.6897
0.2626
A1 > 0.0
K1 > 0.0
A2 > 0.0
K2 > 0.0
Time (min)
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Peptide 22-29 (7)
0.1 1 10 100 1000
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22-29 (7)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
     A2
     K2
Data
22-29 (7)
2.456
0.1175
2.480
0.003126
0.3186
0.04287
0.3003
0.001012
1.746 to 3.166
0.02200 to 0.2130
1.811 to 3.148
0.0008706 to 0.005380
10
0.9623
1.040
0.3226
A1 > 0.0
K1 > 0.0
A2 > 0.0
K2 > 0.0
Time (min)
Peptide 22-29 (7)
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22-29 (7)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
     A2
     K2
Data
22-29 (7)
2.921
0.1259
3.285
0.004088
0.3967
0.04694
0.3800
0.001133
2.037 to 3.805
0.02128 to 0.2304
2.438 to 4.131
0.001565 to 0.006612
10
0.9693
1.450
0.3807
A1 > 0.0
K1 > 0.0
A2 > 0.0
K2 > 0.0
Time (min)
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Peptide 31-46 (15)
0.1 1 10 100 1000
6
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15
31-46 (15)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
31-46 (15)
2.652
0.04569
0.2235
0.01403
2.165 to 3.139
0.01512 to 0.07626
12
0.8351
2.782
0.4815
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 31-46 (15)
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31-46 (15)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
31-46 (15)
3.697
0.01096
0.1593
0.002037
3.350 to 4.044
0.006521 to 0.01540
12
0.9084
2.034
0.4117
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 31-46 (15)
0.1 1 10 100 1000
6
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12
15
31-46 (15)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
31-46 (15)
3.691
0.01892
0.1900
0.003779
3.277 to 4.105
0.01069 to 0.02716
12
0.8829
2.552
0.4611
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 31-46 (15)
0.1 1 10 100 1000
6
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15
31-46 (15)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
31-46 (15)
3.691
0.01892
0.1900
0.003779
3.277 to 4.105
0.01069 to 0.02716
12
0.8829
2.552
0.4611
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 40-46 (6)
0.1 1 10 100 1000
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40-46 (6)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
40-46 (6)
1.550
1.307
2.494
0.008601
0.3722
0.5453
0.1210
0.001277
0.7213 to 2.380
0.09204 to 2.522
2.224 to 2.763
0.005755 to 0.01145
10
0.9766
0.3528
0.1878
Time (min)
Peptide 40-46 (6)
0.1 1 10 100 1000
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40-46 (6)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
40-46 (6)
2.256
0.1996
0.7595
0.004830
0.2089
0.05649
0.1879
0.003038
1.791 to 2.722
0.07373 to 0.3254
0.3408 to 1.178
0.0 to 0.01160
10
0.9692
0.4569
0.2138
Time (min)
78
Peptide 40-46 (6)
0.1 1 10 100 1000
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40-46 (6)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
40-46 (6)
1.700
0.1157
1.619
0.006087
0.7957
0.1147
0.8081
0.006400
0.0 to 3.500
0.0 to 0.3751
0.0 to 3.447
0.0 to 0.02056
9
0.8218
2.840
0.5617
Time (min)
Peptide 40-46 (6)
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40-46 (6)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
40-46 (6)
1.346
1.212
2.685
0.008819
0.4722
0.7723
0.1666
0.001645
0.2940 to 2.398
0.0 to 2.933
2.314 to 3.056
0.005153 to 0.01248
10
0.9612
0.6336
0.2517
Time (min)
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Peptide 42-46 (4)
0.1 1 10 100 1000
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5
42-46 (4)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
42-46 (4)
2.035
0.1795
0.4511
0.003628
0.1419
0.03868
0.1255
0.002795
1.719 to 2.351
0.09328 to 0.2657
0.1714 to 0.7308
0.0 to 0.009856
10
0.9785
0.2331
0.1527
Time (min)
Peptide 42-46 (4)
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5
42-46 (4)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
42-46 (4)
1.295
0.8027
2.607
0.007324
0.2766
0.3801
0.1310
0.001091
0.6788 to 1.911
0.0 to 1.650
2.315 to 2.899
0.004894 to 0.009754
10
0.9754
0.3686
0.1920
Time (min)
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Peptide 42-46 (4)
42-46 (4)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
42-46 (4)
1.867
1.696
2.994
0.01448
1.079
1.559
0.3399
0.004937
0.0 to 4.307
0.0 to 5.222
2.226 to 3.763
0.003315 to 0.02565
9
0.9244
1.827
0.4506
Time (min)
81
Peptide 45-47 (2)
0.1 1 10 100 1000
0
1
2
45-47 (2)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
45-47 (2)
1.845
0.001072
0.02757
0.0001580
1.785 to 1.906
0.0007277 to 0.001416
12
0.8244
0.08853
0.08589
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 45-47 (2)
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45-47 (2)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
45-47 (2)
0.8161
0.07547
0.07951
0.02636
0.6428 to 0.9893
0.01804 to 0.1329
12
0.8044
0.2927
0.1562
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 45-47 (2)
0.1 1 10 100 1000
0
1
2
45-47 (2)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
45-47 (2)
0.6800
2.169
1.198
0.001467
0.2221
0.8880
0.03333
0.0002466
0.1777 to 1.182
0.1601 to 4.177
1.123 to 1.273
0.0009088 to 0.002025
9
0.9301
0.04746
0.07262
Time (min)
Peptide 45-47 (2)
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45-47 (2)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
45-47 (2)
1.912
0.001425
0.04533
0.0002725
1.814 to 2.011
0.0008310 to 0.002019
12
0.7610
0.2355
0.1401
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 47-52 (5)
0.1 1 10 100 1000
0
1
2
3
4
5
47-52 (5)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
47-52 (5)
2.235
0.001367
0.03869
0.0001964
2.150 to 2.319
0.0009393 to 0.001795
12
0.8393
0.1720
0.1197
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 47-52 (5)
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double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
47-52 (5)
2.100
0.001506
1.287
2.344
0.02750
0.0001238
0.2125
0.4616
2.039 to 2.161
0.001230 to 0.001782
0.8132 to 1.760
1.315 to 3.372
10
0.9804
0.04038
0.06354
Time (min)
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Peptide 47-52 (5)
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47-52 (5)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
47-52 (5)
2.396
0.0008940
0.03192
0.0001351
2.326 to 2.465
0.0005997 to 0.001188
12
0.8168
0.1197
0.09986
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 47-52 (5)
0.1 1 10 100 1000
0
1
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5
47-52 (5)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
47-52 (5)
2.662
0.001425
0.05148
0.0002223
2.550 to 2.774
0.0009409 to 0.001910
12
0.8179
0.3037
0.1591
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 48-52 (4)
0.1 1 10 100 1000
0
1
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4
5 48-52 (4)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
48-52 (4)
0.8248
0.04541
0.09107
0.01699
0.6244 to 1.025
0.008020 to 0.08280
11
0.7973
0.3707
0.1836
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 48-52 (4)
0.1 1 10 100 1000
0
1
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4
5 48-52 (4)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
48-52 (4)
1.155
0.004799
0.09068
0.001823
0.9574 to 1.353
0.0008270 to 0.008772
12
0.5993
0.8085
0.2596
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 48-52 (4)
0.1 1 10 100 1000
0
1
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4
5 48-52 (4)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
48-52 (4)
1.513
0.001434
0.09854
0.001006
1.293 to 1.732
0.0 to 0.003675
10
0.1862
0.7756
0.2785
A1 > 0.0
K1 > 0.0
13
1
Time (min)
Peptide 48-52 (4)
0.1 1 10 100 1000
0
1
2
3
4 48- 2 (4)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
48-52 (4)
2.195
0.07873
0.3165
0.03895
1.498 to 2.891
0.0 to 0.1644
11
0.5964
3.742
0.5832
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 49-52 (3)
0.1 1 10 100 1000
0
1
2
3 49-52 (3)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
49-52 (3)
1.400
0.001636
0.03549
0.0003062
1.322 to 1.477
0.0009684 to 0.002303
12
0.7645
0.1429
0.1091
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 49-52 (3)
0.1 1 10 100 1000
0
1
2
3 49-52 ( )
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
49-52 (3)
1.061
2.185
0.4942
0.008490
0.2690
0.7262
0.05012
0.002826
0.4618 to 1.660
0.5673 to 3.803
0.3825 to 0.6058
0.002193 to 0.01479
10
0.9386
0.07503
0.08662
Time (min)
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Peptide 49-52 (3)
0.1 1 10 100 1000
0
1
2
3 49-52 (3)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
49-52 (3)
0.9907
0.002306
0.04833
0.0009012
0.8843 to 1.097
0.0003221 to 0.004289
11
0.4592
0.2225
0.1422
A1 > 0.0
K1 > 0.0
13
1
Time (min)
Peptide 49-52 (3)
0.1 1 10 100 1000
0
1
2
3 49-52 (3)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
49-52 (3)
1.263
0.002550
0.06732
0.0007921
1.117 to 1.410
0.0008238 to 0.004276
12
0.6114
0.4932
0.2027
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 49-53 (4)
0.1 1 10 100 1000
0
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4
49-53 (4)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
49-53 (4)
1.308
2.533
2.498
0.001939
0.3968
0.8824
0.04726
0.0001971
0.4242 to 2.192
0.5668 to 4.499
2.392 to 2.603
0.001499 to 0.002378
10
0.9643
0.1170
0.1082
Time (min)
Peptide 49-53 (4)
0.1 1 10 100 1000
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49-53 (4)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
49-53 (4)
0.6396
0.02592
1.949
0.001694
0.2212
0.01329
0.2271
0.0004497
0.1466 to 1.132
0.0 to 0.05554
1.443 to 2.454
0.0006922 to 0.002696
10
0.9833
0.05768
0.07595
Time (min)
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Peptide 49-53 (4)
0.1 1 10 100 1000
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49-53 (4)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
49-53 (4)
0.5451
1.246
2.530
0.001544
0.1404
0.5356
0.03453
0.0001235
0.2322 to 0.8580
0.05312 to 2.440
2.453 to 2.607
0.001269 to 0.001819
10
0.9749
0.05457
0.07387
Time (min)
Peptide 49-53 (4)
0.1 1 10 100 1000
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49-53 (4)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
49-53 (4)
2.264
0.002279
0.04971
0.0003072
2.156 to 2.373
0.001609 to 0.002948
12
0.8747
0.2723
0.1506
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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54-62 (8)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
54-62 (8)
1.275
0.5848
2.262
0.03397
0.1945
0.2139
0.1922
0.004480
0.8420 to 1.709
0.1081 to 1.061
1.833 to 2.690
0.02399 to 0.04395
10
0.9937
0.1337
0.1156
Peptide 54-62 (8)
Time (min)
0.1 1 10 100 1000
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54-62 (8)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
54-62 (8)
3.726
0.001775
1.581
0.09936
0.1252
0.0002173
0.1337
0.02374
3.447 to 4.004
0.001291 to 0.002260
1.283 to 1.879
0.04646 to 0.1523
10
0.9875
0.2011
0.1418
Peptide 54-62 (8)
Time (min)
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54-62 (8)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
54-62 (8)
3.696
0.001758
1.442
0.06710
0.2325
0.0003540
0.2324
0.02745
3.178 to 4.214
0.0009695 to 0.002547
0.9242 to 1.960
0.005931 to 0.1283
10
0.9723
0.4180
0.2044
Peptide 54-62 (8)
Time (min)
0.1 1 10 100 1000
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54-62 (8)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
54-62 (8)
3.171
0.001843
1.783
0.08532
0.1139
0.0002237
0.1181
0.01536
2.917 to 3.425
0.001344 to 0.002341
1.520 to 2.047
0.05110 to 0.1195
10
0.9918
0.1384
0.1176
Peptide 54-62 (8)
Time (min)
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Peptide 65-72 (7)
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65-72 (7)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
65-72 (7)
1.748
1.857
1.938
0.01109
0.6128
0.9504
0.1505
0.002579
0.3824 to 3.113
0.0 to 3.974
1.603 to 2.273
0.005340 to 0.01683
10
0.9414
0.5423
0.2329
Time (min)
Peptide 65-72 (7)
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65-72 (7)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
65-72 (7)
3.036
0.002366
0.9088
0.6966
0.1005
0.0003343
0.2476
0.4275
2.812 to 3.260
0.001621 to 0.003111
0.3573 to 1.460
0.0 to 1.649
10
0.9477
0.3601
0.1898
Time (min)
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Peptide 65-72 (7)
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65-72 (7)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
65-72 (7)
1.395
0.1229
1.591
0.003605
0.2135
0.05213
0.2026
0.001156
0.9198 to 1.871
0.006800 to 0.2391
1.140 to 2.042
0.001031 to 0.006180
10
0.9572
0.4458
0.2111
Time (min)
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Peptide 73-78 (5)
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73-78 (5)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
73-78 (5)
0.8943
0.6287
0.1239
0.1869
0.6243 to 1.164
0.2213 to 1.036
12
0.8912
0.1295
0.1039
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 73-78 (5)
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73-78 (5)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
73-78 (5)
2.356
0.3491
0.3210
0.1320
1.656 to 3.055
0.06151 to 0.6368
12
0.7490
1.641
0.3698
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 73-78 (5)
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73-78 (5)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
73-78 (5)
2.029
0.6839
0.2642
0.1836
1.454 to 2.605
0.2840 to 1.084
12
0.8707
0.5280
0.2098
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 73-78 (5)
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73-78 (5)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
73-78 (5)
1.855
0.4060
0.1887
0.1077
1.444 to 2.267
0.1713 to 0.6407
12
0.9101
0.4893
0.2019
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 82-92 (10)
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10 82-92 (10)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
82-92 (10)
3.195
0.006939
0.1319
0.001321
2.907 to 3.482
0.004060 to 0.009817
12
0.8710
1.569
0.3616
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 82-92 (10)
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single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
82-92 (10)
1.352
0.01079
0.1161
0.004012
1.099 to 1.605
0.002047 to 0.01953
12
0.7104
1.084
0.3005
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 82-92 (10)
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10 82-92 (10)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
82-92 (10)
3.585
0.003686
0.1416
0.0007457
3.276 to 3.894
0.002061 to 0.005311
12
0.8167
2.072
0.4156
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 82-92 (10)
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10 82-92 (10)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
82-92 (10)
3.009
0.003435
0.1347
0.0008030
2.716 to 3.303
0.001685 to 0.005184
12
0.7276
1.897
0.3976
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 110-116 (6)
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110-116 (6)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
110-116 (6)
2.830
0.2519
0.7559
0.002474
0.3091
0.08700
0.2275
0.002698
2.141 to 3.519
0.05805 to 0.4457
0.2489 to 1.263
0.0 to 0.008485
10
0.9401
1.188
0.3446
Time (min)
Peptide 110-116 (6)
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110-116 (6)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
110-116 (6)
3.447
0.1745
2.441
0.001683
0.3327
0.05388
0.2741
0.0008132
2.705 to 4.188
0.05447 to 0.2946
1.830 to 3.052
0.0 to 0.003495
10
0.9580
1.524
0.3904
Time (min)
100
Peptide 110-116 (6)
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110-116 (6)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
110-116 (6)
3.444
0.3295
1.414
0.004386
0.3792
0.1064
0.2662
0.002463
2.599 to 4.289
0.09237 to 0.5667
0.8210 to 2.007
0.0 to 0.009874
10
0.9538
1.462
0.3824
Time (min)
Peptide 110-116 (6)
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110-116 (6)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
110-116 (6)
2.983
0.002393
2.516
0.1135
0.3475
0.0008602
0.3737
0.04792
2.209 to 3.757
0.0004760 to 0.004309
1.683 to 3.349
0.006758 to 0.2203
10
0.9480
1.557
0.3946
Time (min)
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Peptide 113-116 (3)
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113-116 (3)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
113-116 (3)
1.767
0.06578
0.1213
0.01633
1.503 to 2.031
0.03021 to 0.1014
12
0.8695
0.7187
0.2447
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 113-116 (3)
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113-116 (3)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
113-116 (3)
0.6210
0.03705
0.05047
0.01090
0.5110 to 0.7309
0.01329 to 0.06080
12
0.8048
0.1522
0.1126
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 113-116 (3)
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113-116 (3)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
113-116 (3)
0.7288
0.007294
0.07206
0.003322
0.5718 to 0.8859
5.6509e-005 to 0.01453
12
0.5298
0.4614
0.1961
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 117-124 (7)
0.1 1 10 100 1000
0
2
4
6
8 117-124 (7)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
117-124 (7)
0.8951
0.2114
0.1147
0.08808
0.6452 to 1.145
0.01950 to 0.4033
12
0.8078
0.3277
0.1653
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 117-124 (7)
0.1 1 10 100 1000
0
2
4
6
8 117-124 (7)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
117-124 (7)
2.552
0.002803
0.09298
0.0005723
2.349 to 2.754
0.001556 to 0.004050
12
0.7705
0.9297
0.2784
A1 > 0.0
K1 > 0.0
14
1
Time (min)
104
Peptide 117-124 (7)
0.1 1 10 100 1000
0
2
4
6
8 117-124 (7)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
117-124 (7)
1.854
0.003233
0.09196
0.0008528
1.654 to 2.055
0.001375 to 0.005091
12
0.6753
0.8920
0.2726
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 117-124 (7)
0.1 1 10 100 1000
0
2
4
6
8 117-124 (7)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
117-124 (7)
2.247
0.003333
0.1075
0.0008410
2.013 to 2.481
0.001501 to 0.005166
12
0.7184
1.214
0.3181
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 117-125 (8)
0.1 1 10 100 1000
0
2
4
6
8
117-125 (8)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
117-125 (8)
1.644
1.064
2.336
0.002142
0.3381
0.3998
0.09738
0.0004201
0.8904 to 2.397
0.1732 to 1.954
2.119 to 2.553
0.001206 to 0.003079
10
0.9400
0.3926
0.1981
Time (min)
Peptide 117-125 (8)
0.1 1 10 100 1000
0
2
4
6
8
117-125 (8)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
117-125 (8)
1.103
0.1001
0.07826
0.02505
0.9329 to 1.274
0.04551 to 0.1547
12
0.9052
0.2501
0.1444
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 117-125 (8)
0.1 1 10 100 1000
0
2
4
6
8
117-125 (8)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
117-125 (8)
2.222
0.009844
0.1877
0.003657
1.813 to 2.631
0.001875 to 0.01781
12
0.5963
2.901
0.4916
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 117-125 (8)
0.1 1 10 100 1000
0
2
4
6
8
117-125 (8)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
117-125 (8)
1.919
0.02010
0.1203
0.004831
1.657 to 2.181
0.009577 to 0.03063
12
0.8233
1.010
0.2901
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 125-128 (3)
0.1 1 10 100 1000
0
1
2
3
4 125-128 (3)
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Data
     Number of X values
     Number of Y replicates
     Total number of values
     Number of missing values
2.893
1.057
0.2018
0.1214
2.453 to 3.332
0.7923 to 1.321
12
0.9789
0.1704
0.1192
14
1
14
0
Time (min)
1 10 100 1000
-1
0
1
2
3
4
5
6
7
Peptide 127-133 (6)
127-133 (6)
 
double exponential
Best-fit values
     A1
     K1
     A2
     K2
Std. Error
     A1
     K1
     A2
     K2
95% Confidence Intervals
     A1
     K1
     A2
     K2
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
127-133 (6)
4.948
1.207
2.313
0.02180
0.3161
0.1571
0.1622
0.003190
4.233 to 5.663
0.8513 to 1.562
1.946 to 2.680
0.01458 to 0.02901
9
0.9948
0.2514
0.1671
A1 > 0.0
Time (min)
108
Peptide 125-133 (8)
0.1 1 10 100 1000
0
2
4
6
8
10 125-133 (8)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
125-133 (8)
2.6550e+006
63.46
7.4717e+012
1.1278e+007
0.0 to 1.6445e+013
0.0 to 2.4823e+007
11
0.3291
0.1699
0.1243
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 125-133 (8)
0.1 1 10 100 1000
0
2
4
6
8
10 125-133 (8)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
125-133 (8)
3.967
2.283
0.7966
0.5013
2.231 to 5.702
1.191 to 3.375
12
0.8471
0.7301
0.2467
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Peptide 125-133 (8)
0.1 1 10 100 1000
0
2
4
6
8
10 125-133 (8)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
125-133 (8)
1.745
2.226
0.5709
0.8065
0.5011 to 2.989
0.4685 to 3.983
12
0.7637
0.3962
0.1817
A1 > 0.0
K1 > 0.0
14
1
Time (min)
Peptide 125-133 (8)
0.1 1 10 100 1000
0
2
4
6
8
10 125-133 (8)
 
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
125-133 (8)
1.103
0.003555
0.06354
0.001059
0.9643 to 1.241
0.001248 to 0.005863
12
0.6471
0.4197
0.1870
A1 > 0.0
K1 > 0.0
14
1
Time (min)
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Subtracted Peptide 31-40(9)
0.1 1 10 100 1000
0
1
2
3
4
5
6
7
8
9
31-40(9) sub
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
     Total number of values
     Number of missing values
0.7606
0.007639
0.07822
0.003581
0.5902 to 0.9311
0.0 to 0.01544
12
0.5442
0.5380
0.2117
A1 > 0.0
K1 > 0.0
14
1
14
0
Time (min)
Subtracted Peptide 31-40(9)
0.1 1 10 100 1000
7
8
9
31-40(9) sub
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
     Total number of values
     Number of missing values
0.1268
0.01040
0.1282
0.04307
0.0 to 0.4089
0.0 to 0.1052
11
0.08937
1.045
0.3082
A1 > 0.0
K1 > 0.0
14
1
13
1
Time (min)
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Subtracted Peptide 31-40(9)
0.1 1 10 100 1000
0
1
2
3
4
5
6
7
8
9
31-40(9) sub
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
     Total number of values
     Number of missing values
0.6716
0.1278
0.1615
0.1052
0.3198 to 1.023
0.0 to 0.3571
12
0.5055
0.9446
0.2806
A1 > 0.0
K1 > 0.0
14
1
14
0
Time (min)
Subtracted Peptide 31-40(9)
0.1 1 10 100 1000
0
1
2
3
4
5
6
7
8
9
31-40(9) sub
single exponential
Best-fit values
     A1
     K1
Std. Error
     A1
     K1
95% Confidence Intervals
     A1
     K1
Goodness of Fit
     Degrees of Freedom
     R squared
     Absolute Sum of Squares
     Sy.x
Constraints
     A1
     K1
Data
     Number of X values
     Number of Y replicates
     Total number of values
     Number of missing values
Does not converge.
Time (min)
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LISTERIA MONOCYTOGENES COMPARISON OF PERCENT FAST EXCHANGE
WITH CRYSTALLOGRAPHIC DISTANCE FROM AMIDE N
TO MN2+ CENTER
Fast Exchange for Mn-bound FosX
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